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ABSTRACT
This dissertation explores the development of analytical methods for studies of CVD
biomarkers and related biomolecular indicators. Initially, spectroscopic studies were
conducted to investigate the chemical reactivity of homocysteine (Hcy), an independent
CVD risk factor and serological biomarker. Consequently, we proposed an alternate theory
for in vivo Hcy clearance based on spontaneous pyridoxal tetrahydrothiazine (PT) formation
from Hcy and pyridoxal. The validity of PT-assisted Hcy clearance was further evaluated
by use of capillary electrophoretic methods, which allowed rapid monitoring of protein
oligomerization in PT-protein reaction mixtures. The results of these studies suggest that
PT formation is a plausible mechanism for Hcy clearance. Moreover, PT formation was
shown to protect proteins from post-translational modification by homocysteine thiolactone.
This dissertation also addresses the need for rapid and direct detection methods for CVD
biomarkers. Accordingly, we introduced the first plasmon resonant GNP sensing scheme
for protein homocystamide.

The nanosensor provides visual conformation of protein

homocystamide (N-Hcy-protein) by way of a red-to-blue color change. Further sensor
investigations conducted with protein nanobioconjugates revealed that the GNP sensing
mechanism is dependent on several complex physiochemical and biomolecular interactions
including nanoparticle self-assembly, interparticle disulfide cross-linking, and modificationinduced protein conformational changes.

This dissertation also continues previous

atherosclerotic tissue characterization studies by demonstrating the feasibility of using
hybrid organic-immunoaffinity extraction for GC-MS analysis of polycyclic aromatic
hydrocarbons in human heart plaque samples. This body of work is significant because it
proposes new bioanalytical technologies that could enhance CVD screening and treatment.
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CHAPTER 1
INTRODUCTION
1.1 Cardiovascular Disease
Cardiovascular disease (CVD) continues to be the leading cause of mortality in the U.S.
According to the American Heart Association (AHA), CVD affects more than 81 million
Americans and accounts for about one in every three deaths in this country.1 Statistics from the
AHA also indicate that high blood pressure (HBP) or hypertension affects approximately 73
million people and is thus the most pervasive form of CVD, followed by heart attack (16
million), stroke (5.8 million), heart failure (5.3 million), and congenital heart defects (1.3
million). Instances of CVD vary significantly among different ethnic groups for reasons that are
not well understood.

Figure 1.1 Racial dependency of coronary heart disease, high blood pressure, and stroke.
1

Figure 1.1 provides a highlight of trends in coronary heart disease (CHD), HBP, and stroke based
on ethnicity as reported by the AHA for individuals 18 years of age and older. The values in
parenthesis indicate the % of CVD within respective ethnic populations. The y-axis of the bar
graph represents the percent of total known CVD instances. African Americans and Native
Americans have the highest instances of HBP and stroke, while CHD is slightly more prevalent
in the Caucasian population.

Atherosclerosis is a common form of CHD that is

disproportionately prevalent in the U.S.
The severity of atherosclerosis is often described as Type I, II, or III. Type I, the onset of
atherosclerosis, is indicated by mild inflammation of the endothelial cells of the arteries. Type II
atherosclerosis is characterized by intimal tissue damage in the arteries and the appearance of
fatty plaques. The most severe stage of atherosclerosis is Type III, which is indicated by blood
clot (thrombus) formation and deep intimal and medial tissue damage.

Figure 1.2 is an

illustration of Type III atherosclerosis in which plaques and blood clots have accumulated in the
left anterior descending artery of the heart. As a result, there is a critical reduction in arterial
blood flow. This severe condition could cause sudden cardiac arrest if left untreated.

arterial plaque

right coronary
artery

blood clot
left anterior descending
artery

Figure 1.2 Illustration of severe atherosclerosis.2
2

Most would agree that affordable healthcare is among the most important issues facing
our society. Based on the aforementioned data and statistics, the economic burden of CVDrelated healthcare services in the U.S. is projected to exceed $448.5 billion in 2008.3-5 This
estimate will likely increase significantly in the coming years as those born in the “Baby
Boomer” generation (1946-1964) reach old age. Fortunately, technology is rapidly evolving to
meet the growing demand for diagnostic tools that will allow clinicians to better diagnose and
treat CVD.
Our research group and others worldwide are currently developing the next generation of
biomedical screening methods for use in high-throughput CVD screening applications. The
remainder of this Chapter provides a general review of current bioanalytical screening
technologies as well as other topics relevant to CVD including biomarkers, vitamin B, and
polycyclic aromatic hydrocarbons (PAHs). The feasibility of using immunoaffinity extraction as
a means of enhancing PAH characterizations in human atherosclerotic plaques and tissues is also
discussed. This review also addresses recent advances in nanotechnology-based bioanalytical
sensors for detection of thiol-containing biomarkers.
1.1.1 Conventional Risk Factors and Biomarkers
The complexity of CVD makes it extremely difficult to identify specific sources of
pathogenesis. For this reason, physicians and biomedical researchers are constantly searching
for new CVD risk factors and biomarkers for use in clinical diagnosis. Risk factors are either
inherent human characteristics or preventable behaviors that correlate with the occurrence of a
particular disease.

Inherent CVD risk factors cannot be treated and include age, gender,

congenital defects, and race. In general, the inherent risk of atherosclerosis increases with age
and males tend to be more susceptible to CVD than women. Conversely, preventable risk factors

3

can be effectively moderated by treatment and or behavior modification.
The most well-known preventable CVD risk factors include tobacco smoking, high blood
cholesterol (HBC), HBP, sedentary lifestyle, obesity, diabetes, stress, and alcohol abuse.
Smoking is perhaps the most controversial of all preventable CVD risk factors because nonsmokers are often inadvertently subjected to second-hand tobacco smoke. For this reason, many
municipalities worldwide have moved to protect public health and safety by prohibiting tobacco
use in most public places. Analogous public health initiatives are being launched in the U.S. to
combat HBC. California was the first state to ban the use of HBC-inducing trans fatty acids in
fast food cuisine (2010) and baked goods (2011).6 Most individuals can moderate their HBC by
adopting a low-fat diet. In other cases, the use of cholesterol-lowering medications may be
necessary.
Being overweight also increases ones risk of CVD. Excess fat in the abdominal area is
thought to be especially detrimental to cardiovascular health.7 In contrast, maintaining a normal
weight and enacting lifestyle changes such as becoming physically active, reducing stress, and
avoidance of alcohol abuse are beneficial factors. Diabetes mellitus is also classified as a
preventable risk factor. Surprisingly, approximately 75% of diabetics eventually succumb to
CVD-related complications.8 For this reason, it is critical for diabetics to take every available
precaution to control their blood glucose levels and weight.
Disease biomarkers are measurable and quantifiable characteristics associated with a
pathological process.9 Based on this definition, some CVD risk factors including HBP and HBC
are also classified as biomarkers. Serological CVD biomarkers are found in the blood or serum.
Conventional serological CVD biomarkers such as cholesterol, inflammation indicators, and
natriuretic peptides have been thoroughly reviewed in the literature and will not be discussed

4

here.9-15 Alternatively, a general reference list of current serological biomarkers and associated
CVD indicators is provided in Table 1.1. The biomarkers in the general category are considered
novel because their pathological functions are not yet well understood.

The amino acid

homocysteine is of particular interest because there is fervent disagreement within the
biomedical community about its significance to CVD (vide infra).
Table 1.1 General reference list of current serological CVD biomarkers. (adapted from ref. 9)

1.1.2 Homocysteine as a Cardiovascular Disease Biomarker
Homocysteine (Hcy) is a sulfur-containing, nonproteinogenic amino acid that is produced
in the body as an intermediate species in protein synthesis. Hcy has two major metabolic fates,
conversion to methionine via remethylation pathway and conversion to cysteine (Cys) via
transsulfuration pathway.16 The remethylation pathway is catalyzed by vitamin B12 and folic
acid, while the transsulfuration pathway is catalyzed by vitamin B6 (Figure 1.3). Individuals with
vitamin B deficiencies or congenital metabolic defects are often incapable of maintaining normal
Hcy levels. Consequently, intracellular Hcy levels rapidly increase until the cell is forced to
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excrete Hcy into the bloodstream, thereby resulting in elevated serum Hcy levels. This condition
is

known

as

hyperhomocysteinemia.

The

scale

used

for

clinical

diagnosis

of

hyperhomocysteinemia is 1) moderate (10-30 μM), 2) intermediate (30-100 μM), and 3) severe
(≥100 μM).

Protein (diet)

methionine

B12

Metabolic Fates of Hcy
1. remethylated to methionine

Demethylation Pathway

B9

3. vitamin B deficiency can
cause intercellular
accumulation

homocysteine (nonproteinogenic)

B6

2. converted to cysteine

Transsulfuration Pathway
4. elevated levels in blood
and urine.

cysteine (proteinogenic)
6

Figure 1.3 Schematic of in vivo homocysteine metabolism.
Hyperhomocysteinemia is believed to directly affect cardiovascular proteins. Excess Hcy
may alter the biochemical properties of arterial surfaces, thereby inducing lesions and the onset
of atherosclerosis. This theory was initially proposed by Kilmer McCully in 1969 after observing
damage to cultured endothelial cells caused by the presence of Hcy.17 McCully and a team of
biomedical researchers subsequently demonstrated that the severity of atherosclerotic lesions and
tissue damage in rabbits were directly proportionate to the amount of Hcy injected
intravenously.18 These early observations inspired the direct toxicity model, which identified
Hcy as a causative agent in atherosclerosis.19 Despite its scientific merit, the direct toxicity
model was not well received in 1971 because it appeared to contradict the widely accepted
6

cholesterol-CVD hypothesis, which identified cholesterol as the root cause of heart disease. The
ensuing controversy culminated with the loss of McCully’s research funding and prestigious
faculty positions at the Harvard Medical School and Massachusetts General Hospital in 1979.
Nevertheless, McCully continued his research in relative obscurity at the Providence Rhode
Island Veterans Hospital.

He was finally vindicated in 1997 when a major clinical study

concluded that CVD risk increased proportionately with every 10% increase in blood Hcy levels
above normal (≤10 μM).20
Today, physicians often consider Hcy along with cholesterol and other risk indicators
when diagnosing CVD. Representative blood Hcy concentration values measured in normal
individuals and hyperhomocysteinemia patients are listed in Table 1.2. These data suggest that
some individuals with hyperhomocysteinemia have Hcy levels that exceed normal levels by
more than 10-fold. Hyperhomocysteinemia patients also tend to have higher concentrations of
protein-bound Hcy levels. Protein-bound Hcy is not yet classified as a CVD biomarker. N-Hcyprotein is presumed to be the most physiologically relevant form of protein-bound Hcy (vide
infra).
Table 1.2 Blood homocysteine levels in normal and hyperhomocysteinemia patients.21

7

Epidemiological studies suggest that vitamin B effectively lowers blood Hcy levels and
the risk for CVD.22-25 Intramuscular injections containing a combination of vitamins B12, B6,
and folic acid have been shown to moderate hyperhomocysteinemia in 84% of elderly subjects as
compared to only 20% taking a placebo.26 This outcome was mirrored in a similar study that
administered a combination of folic acid and vitamin B6.27 Single daily supplements of either
B6, folic acid, or B12 also help mediate blood Hcy levels.28 The Hcy-lowering effect of vitamin
B has been largely attributed to metabolic processes; however, nonenzymatic mechanisms for
Hcy clearance may also exist.29 The chemical structures of selected forms of vitamins B are
shown in Figure 1.4.
Pyridoxal-5-Phosphate (B6)

Folic Acid (B9)

Cobalamine (B12)

Figure 1.4 Chemical structures of selected forms of vitamin B.
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There is also a wealth of information in the literature pertaining to vitamin B content in
atherosclerotic tissues. Representative values for Vitamin B content in autopsied normal and
atherosclerotic aortic tissues are shown in Table 1.3. With the exception of folic acid, vitamin B
content in normal tissue is considerably higher than in atherosclerotic tissue. Note that vitamin
content is expressed as % concentration vitamin B detected in normal pulmonary or vena cava
tissues from the same subject. These data reinforce the relationship between vitamin B and
CVD.
Table 1.3 Vitamin B content values in normal and atherosclerotic heart tissues.30
Vitamin

normal tissue
% content
(standard deviation),
n = no. of subjects

atherosclerotic tissue
% content
(standard deviation),
n = no. of subjects

Thiamine (B1)

107.7 (0.83); n = 32

78.4 (2.42); n = 10

Riboflavin (B2)

124.8 (6.43); n = 27

76.7 (6.95); n = 17

Nicotinic acid (B3)

120.1 (3.42); n = 11

not reported

Pyridoxal-5-phosphate (B6) 122.6 (4.22); n = 45

80.9 (4.02); n = 56

Folic acid (B9)

86.8 (2.54); n = 14

84.7 (1.34); n = 6

Cobalamine (B12)

191.0 (5.82); n = 14

97.2 (0.10); n = 27

1.1.3 N-Homocysteine-Protein
The function of Hcy in the pathogenesis of CVD is poorly understood. However, there is
compelling evidence that suggests Hcy thiolactone (HTL), a metabolite of Hcy, may trigger the
onset of CVD.31-33 HTL is a reactive thioester compound synthesized in vivo through enzymatic
aminoacyl-tRNA synthase pathways at a rate proportional to extracellular Hcy concentration.34
Hence, HTL production is likely elevated in individuals with hyperhomocysteinemia.35
Increased in vivo production of HTL is known to induce pathogenic effects such as vascular
9

protein and tissue damage, which may induce early atherosclerotic lesion formation.36

It has

also been shown that HTL readily and preferentially reacts with proteins at the ε-amino groups
of lysine residues under physiological conditions to yield protein homocystamide (N-Hcyprotein) species.21, 37 HTL modification can be detrimental to protein function because it may
lead to spontaneous intermolecular disulfide bonding to yield protein oligomers (Figure 1.5).38
N-Hcy-protein also exhibits decreased biological activity, lower solubility, and increased
immunogenicity.39 Moreover, a recent clinical study has revealed a positive correlation between
plasma N-Hcy-protein levels and instances of major diseased coronary vessels in 254 subjects.40

Figure 1.5 Post-translational protein modification via N-homocysteinylation.
1.2 Conventional Bioanalytical Methods for Homocysteine Analysis
Given the biomedical significance of Hcy as a CVD biomarker, there is demand for
accurate and reliable diagnostics for Hcy.

Bioanalytical chemists have responded to this

challenge by engineering a variety of methods and techniques. Hcy diagnostic methods are
typically classified as either direct or indirect methods. Direct methods of Hcy analysis are
usually rapid and require minimal sample preparation. In contrast, indirect methods tend to be
time-consuming and laborious due to complicated sample derivatization, separation, and
purification steps. One commonality between direct and indirect Hcy diagnostics is the necessity
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for sample pretreatment with a disulfide reducing agent in order to liberate oxidized species. The
most extensively used aqueous-soluble disulfide reducing agents include 2-mercaptoethanol,
dithiothreitol, and 2-carboxyethyl phosphine. The remainder of this chapter provides a brief
review of conventional chromatographic, electrophoretic, and immunoaffinity-based methods for
analysis of Hcy and related biomolecules. The perceived advantages and disadvantages of each
method are also discussed.
1.2.1 Chromatographic Methods
Hcy is found in serum and thus must be separated from a multitude of complex sample
components prior to detection. In general, chromatographic methods accomplish analytical
separations within a packed column by way of selective partitioning of the analytes between a
mobile phase and a stationary phase. The separation can be monitored either on-column or postcolumn. GC-MS, high-performance liquid chromatography (HPLC), and ion exchange
chromatography (IEC) are the most popular indirect methods for Hcy analysis.
The appeal of GC-MS in modern clinical laboratories is waning because biomolecules
such as Hcy must undergo tedious chemical derivatization to increase volatility and thermal
stability prior to GC separation. HPLC is perhpas the most widely used method of analysis for
Hcy because the instrumentation is widely available in clinical laboratories. Reversed phase
HPLC systems utilize a polar-aqueous mobile phase and a hydrophobic stationary phase (e. g. C8
and C18), which are more compatible with biomolecules.

Furthermore, HPLC is widely

applicable to Hcy analyses because it readily accommodates photometric, fluorometric,
electrochemical and MS detectors. IEC is primarily used as a sample clean-up technique prior to
detection with an amino acid analyzer. IEC discriminates among biomolecules such as proteins,
nucleic acids, and amino acids based on electrostatic interactions. Perhaps the most attractive
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feature of chromatographic methods is the availability of numerous detection formats.
Conversely, the cost associated with operation and maintenance of chromatographic systems can
be relatively higher.
1.2.2 Electrophoretic Methods
Capillary electrophoresis (CE) is a high-performance separation technique that has
become a viable alternative to chromatographic methods for Hcy analysis. Capillary zone
electrophoresis (CZE), the simplest mode of CE, is performed by inducing electroosmotic flow
within a micro-bore fused silica capillary filled with an electrolyte solution. The result is nearplug flow, which provides rapid and highly efficient separation of charged analytes based on the
principle of electrophoretic mobility.

The major advantages of CE over chromatographic

methods include shorter analysis times, higher peak efficiencies, and lower sample-reagent
consumption. The basic apparatus for CE includes a fused silica capillary, buffer reservoirs, a
high voltage power supply, and a detection system. A schematic of a CE instrument is provided
in Figure 1.6.

Detection options for CE are essentially the same as those listed for LC.

However, CE is generally less concentration sensitive than HPLC methods due to the shorter
optical path length of the capillary. Protein wall-adsorption is also a potential problem. Recent
innovations in CE Hcy analysis are reviewed in the literature and will not be discussed here.41, 42
Although CE has become a viable option for protein separations, sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) is by far the most commonly used method.
SDS is an anionic surfactant that binds with protein molecules such that all species have identical
charge-to-mass ratios. The resultant protein-SDS conjugates are subjected to electrophoresis
within a molecular sieving gel matrix that facilitates separation based on size. The separation is
usually visualized by staining the gel with a protein-specific dye such as coomasie blue. Our
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research group and others have used both CE and SDS-PAGE for analysis of N-Hcy-protein
(vide infra).

Figure 1.6 Diagram of capillary electrophoresis instrument.
1.2.3 Immunochemical-Based Assays
Immunoassays (IAs) exploit the strong and selective affinity interactions of antibodies.
The most popular IA format is the enzyme-linked immunosorbent assay (ELISA) method. In its
simplest form, ELISA involves the immobilization or bioconjugation of antibodies to a solid
support. The conjugated antibody is then incubated in a solution containing the target analyte
and allowed to bind.

The support is rinsed between sample applications to remove non-

specifically bound sample constituents. Detection is usually achieved by introducing specially
labeled detection antibodies that produce a colorimetric response upon the addition of an
enzyme. Fluorescently labeled antibodies can also be employed to achieve greater analytical
sensitivity.

ELISA is gradually replacing HPLC as the preferred method for many clinical

screening applications because it is relatively inexpensive, less laborious, and more conducive to
high-throughput platforms such as 96-well plates. Various ELISA-based Hcy detection methods
have been reported, some of which are commercially available as kits.43-45 The advantages and
disadvantages of current bioanalytical technologies for Hcy analysis are summarized in Table
1.4.
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Table 1.4 Comparison of conventional bioanalytical methods. (adapted from ref. 75)
Method (detection)*

Advantages

Disadvantages

GC-isotopic dilution
(MS)

-excellent accuracy and precision
-applicable to determination of other
amino thiols
-superior sensitivity

-MS required
-derivatization
-complex instrumentation

HPLC (MS-MS)

-no derivatization required
-good accuracy and precision
achievable using internal standard

- requires expensive MS-MS and
deuterated internal standards
-complex instrumentation

HPLC (PD)

-high sensitivity (<50 nM)
-high precision (1.2 - 2.5 %)
-more user friendly than LCMS

-post-column derivatization
required for optimum sensitivity

HPLC (FD)

-high sensitivity (not reported)
-high precision (1.0 – 4.8 %)
-more user friendly than LC-MS

-pre-column derivatization
-difficult to automate

HPLC (ECD)

-no derivatization required
-comparable analytical performance
to other HPLC methods

-susceptible to contamination
and electrode fouling

IEC

-serves as a simplistic sample
clean-up method
-easily automated

-requires post-column
derivatization if amino acid
analyzer is used

CE (FD)

-shorter analysis time than
chromatographic methods
-less laborious than HPLC
-lower sample and solvent
Consumption
-easily automated

-CE inherently less sensitive than
chromatographic methods
-FD usually required to achieve
adequate sensitivity

IA (FD, CLD,
enzymatic)

-superior selectivity
-very user friendly
-ELISA kits commercially available
-high-throughput (96 well ELISA)

-only L-Hcy can be analyzed
-limited dynamic range
-higher reagent cost than HPLC
or CE
-difficult to standardize
-antibodies produced in animals

*

MS-MS = tandem mass spectrometry; PD = photometric detection; FD = fluorescence
detection; ECD = electrochemical detection; CLD = chemiluminescence detection.
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1.3 Direct Visual Detection of Homocysteine
One common disadvantage of conventional bioanalytical methods for Hcy analysis is the
lack of analytical selectivity for the N-Hcy-protein fraction of serum. To date, most methods are
only capable of determining total Hcy (Hcyt), which consist of both free and protein-bound Hcy.
Researchers have attempted to adapt conventional methods for use in N-Hcy-protein detection.
However, the resulting procedure is often more costly, complicated, and laborious. For example,
some modified HPLC methods require several additional steps including acid hydrolysis, IEC
purification, and post-column labeling.46, 47 Although ELISA shows great promise for N-Hcyprotein analysis, method development has been greatly hindered by the lack of commercially
available N-Hcy-protein antibodies.
Direct visual detection is the latest trend in bioanalytical analysis. Our laboratory has
collaborated in the development of several organic dye-based molecular probes for direct visual
Hcy sensing. These probes were prepared from inexpensive and commercially available
substrates including methyl viologen and fluorine black.48, 49 Organic molecular probes typically
exhibit excellent selectivity for Hcy but are susceptible to non-specific binding to proteins. For
this reason, most organic dye-based probes are not useful for direct detection of N-Hcy-protein.
Nanotechnology provides a versatile platform for addressing the shortcomings of
conventional bioanalytical methods and organic dye-based molecular probes.

Direct

colorimetric detection of Hcy with GNP sensors is based on the principle of localized plasmon
resonance, a phenomenon that occurs when the de Broglie wavelength of colloidal valence
electrons is comparable to colloid particle size.50

Under these conditions, the nanocolloid

behaves as a “theoretical quantum box” that contains oscillating electrons. Localized plasmon
resonance is produced by the oscillating electrons.

15

The frequency of localized plasmon

resonance is strongly dependent on colloidal composition, particle size, shape, and interparticle
distance.51 GNPs (5 to 20 nm) dispersed in aqueous media generally have plasmon resonance
absorption bands in the vicinity of 520 nm.
The utility of colloidal nanoparticles as sensors is based on chemically or biochemically
induced self-assembly.

Nanoparticle self-assembly decreases interparticle distance, which

facilitates plasmon coupling via electron tunneling between particles. The result is diminished
plasmon resonance frequency, which cases a proportionate shift in absorption and characteristic
transitions in solution color from red to purple-violet.52 GNPs (5-20 nm) self-assembled in
aqueous media usually exhibit plasmon absorption maxima at or beyond 620 nm, depending on
the degree of assembly. A diagram of colorimetric sensing with plasmon resonant GNPs is
shown in Figure 1.7.

In this generic example, 10 nm GNPs are subjected to a specific

biochemical stimulus that induces nanoparticle self-assembly and colorimetric response. In
practice, it is often necessary to functionalize the GNPs in order to achieve the desired
biochemical recognition.

Figure 1.7. Plasmon resonant GNP biochemical sensing.
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The concept of plasmon resonant biochemical probes originated more than 40 years ago
when Bloomfield invented a colloidal gold reagent for plasma protein testing.53

Recent

advancements in plasmon resonant biochemical sensors have been reviewed in the literature.54
GNPs have shown great promise for sensing a wide range of physiologically relevant molecules
including carbohydrates,55 and DNA.56, 57 Likewise, GNPs have been used to detect amino thiol
biomarkers including Hcy58, Cys59, and glutathione.59 The first account of plasmon resonance
detection of N-Hcy-protein was recently reported by our research group (vide infra).60
1.4 Spectrochemical Techniques
Spectroscopic methods are an integral part of the research presented in this dissertation.
For example, UV-visible (vis) spectroscopy is used for various analytical applications including
detection in CE separations and GNP protein sensing. Fluorescence spectroscopy is utilized to
assess biomolecular interaction between pyridoxal and Hcy. Additionally, circular dichroism
(CD) spectroscopy is employed to probe protein conformational change on the surfaces of gold
nanobioconjugates.

This section provides a brief introduction to relevant spectrochemical

analysis techniques.
1.4.1 UV-visible Spectroscopy
UV-vis absorption spectroscopy is a molecular characterization technique used for
analysis of molecules that absorb ultraviolet and visible light (photons). The photon absorption
process causes electrons in the analyte molecule to be promoted from the ground energy state to
an excited energy state.

Spectrochemical information about the molecule is obtained by

measuring the magnitude of the electronic transition.61 A spectrophotometer measures the
absorption or transmittance of light by a sample.

A graphic representation of a UV-vis

spectrometer is shown in Figure 1.8. A light source capable of producing UV and visible
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radiation is directed to a diffraction grating, where it is separated into distinct wavelengths. The
desired wavelength of light is then projected through an aperture onto the sample cuvet. The
transmitted light is usually detected by use of a photomultiplier tube or photodiode-array.

Figure 1.8 Graphic representation of a UV-visible spectrometer.62
The absorption spectrum of a sample is obtained by plotting absorption intensity or
absorbance versus excitation wavelength.

UV-vis spectroscopy is useful for analytical

applications because sample absorbance is proportional to concentration as described by the
Beer’s law equation;

, where A is absorbance,

is molar absorptivity, b is the sample

pathlength and c is molar concentration. Based on this relationship, a calibration curve can be
generated to determine the concentration of molecules in unknown samples.
1.4.2 Circular Dichroism Spectroscopy
Circular dichroism (CD) is a variant of absorption spectroscopy that allows one to detect
the chiral signatures of amino acids, RNA, DNA, and other biomolecules. Researchers also use
CD to probe protein structural conformations such as α-helicies and β-sheets and random coils
(Figure 1.9). Molecular excitation for CD is achieved by use of circularly polarized light, which
18

is absorbed preferentially on the basis of differences in the chirality of molecular constituents.63
Hence, the transmitted light becomes elliptically polarized. The term ellipticity (θ) is used to
describe the angular bias of CD resulting from a sample.

Figure 1.9 Theoretical protein ellipticity curves for α-helix (red), β-sheet (blue), and random
coil (yellow) components.64
1.4.3 Fluorescence Spectroscopy
The Jablonski diagram (Figure 1.10) illustrates the processes involved in molecular
fluorescence. Initially, excitation via photon absorption promotes the molecule to an excited
singlet state (Sn). At this point, the molecule encounters both radiative and non-radiative modes
of relaxation to the ground state. Non-radiative relaxation modes include collisional quenching,
internal conversion, and intersystem crossing. Collisional quenching is energy transfer from one
molecule to another by way of collision. Internal conversion is energy loss due to electronic
transitions within the same spin state.

Intersystem crossing refers to electronic transitions
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between spin states of different multiplicities, such as singlet to triplet (Sn to Tn). Fluorescence is
a radiative mode of relaxation that occurs when the molecule transitions from the S1 state to the
ground state (S0). The wavelength of fluorescence emission is red-shifted compared to the
excitation wavelength.61 This effect is known as the Stokes shift. Similarly, radiative relaxation
can result from phosphorescence, which results from T1 to S0 transitions.

Figure 1.10 Jablonski diagram.65
1.5 Mass Spectrometry
Mass spectrometry (MS) is an analytical technique that discriminates charged molecular
species based on mass-to-charge (m/z) ratio. The basic instrumentation required for MS includes
1) ion source, 2) mass analyzer, 3) detector, and 4) data system (Figure 1.11). The purpose of
the ion source is to facilitate ionization of individual analyte molecules.

Ionized sample

components are then accelerated to the mass analyzer, which separates molecular ions according
to m/z by use of magnetic or electric field sectors.

Molecular ion detection is usually

accomplished by converting ion current to electrical signal.
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Upon completion of signal

conversion and data analysis, a mass spectrum is generated by plotting signal intensity versus
m/z.

Figure 1.11 Block diagram of generic mass spectrometer.66
1.6 Bioaccumulation of Polycylic Aromatic Hydrocarbons in Atherosclerotic Tissues
Chemical characterizations of cardiovascular tissues and plaques have greatly enhanced
knowledge of CVD pathology.67-73 Our laboratory has contributed to this effort by evaluating
calcium-hydroxyapatite,74-77 and cholesterol78 content in atherosclerotic plaques and tissues.
These studies have afforded a better understanding of the physiochemical differences between
native and bypass atherosclerotic plaques. PAH content in cardiovascular tissues is also of
interest to biomedical researchers because of the potential for bioaccumulation. PAHs are a class
of toxic, hydrophobic, and potentially carcinogenic environmental pollutants created as
byproducts of combustion.

The solubility and toxicity of PAHs increase upon enzymatic

conversion to more polar metabolites which are more soluble in physiological media. Figure
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1.12 gives the structures for 16 PAHs currently monitored and regulated by the United States
Environmental Protection Agency. Significant levels of PAHs have been detected in the air,79, 80
water sources,81, 82 food products,83, 84 and soil.85, 86 However, very little is known about the PAH
content in atherosclerotic tissues. This is partially due to the lack of selective methods for
extracting PAHs from atherosclerotic plaques and tissues. For this reason, new strategies for
obtaining higher analyte selectivity are explored in this dissertation.

Naphthalene

Anthracene

Pyrene

Benzo[a]pyrene

Fluorene

Acenaphthylene

Phenanthrene

Chrysene

Indeno[1,2,3-cd]pyrene

Fluoranthene

Benzo[a]anthracene

Benzo[b]fluoranthene

Acenaphthene

Benzo[k]fluranthene

Dibenzo[a,h]anthracene

Benzo[g,h,i]perylene

Figure 1.12 Chemical structures for EPA list of priority PAHs.
Immunoaffinity-based methods could help address the need for greater selectivity in the
analysis of PAHs in atherosclerotic plaques and tissues. Immunoaffinity extraction (IAE) is a
technique that uses immobilized antibodies to bind a specific molecular target, thereby
simultaneously extracting and concentrating the target analyte. The primary advantage of IAE is
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its compatibility with complex biological sample matrices.

Figure 1.13 shows a graphic

representation of a PAH antibody. The Fc or constant region of the antibody is covalently
immobilized to an IAE stationary phase. PAH binding occurs at the Fab or binding region of the
antibody, also known as the “binding pocket”.

PAHs

Fab region

Fc region

IAE stationary phase

Figure 1.13 PAH antibody immobilized to an IAE stationary phase.
A process diagram of the IAE cycle for PAH analysis is shown in Figure 1.14. In the
first step, the mobile phase is maintained at physiological pH to facilitate binding of PAH
molecules (green dots) to the immobilized antibodies as the sample is passed through the
column. Non-PAH sample components (red squares and blue dots) do not bind and are thus not
retained on the column. Non-specifically bound sample components are washed off the column
in the second step. In the third step, the mobile phase conditions are changed, usually by
lowering pH, to disrupt the antibody binding and elute the PAH molecules from the column. If
desired, the PAH molecules can be detected for quantification during the elution step prior to
fraction collection. The column is regenerated in the final step by reestablishing the initial
mobile phase conditions. Under ideal conditions, the IAE cycle can be repeated hundreds of
times.

We have proposed a hybrid organic solvent-IAE method for PAH analysis in
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atherosclerotic plaque.

The feasibility of this method is discussed in Chapter 6 of this

dissertation.
complex sample mixture

unbound
fraction
step 2

1. extraction

PAH
fraction
step 3
2. wash

4. regeneration
3. elution
detection

elution profile

Figure1.14 Diagram of IAE cycle and elution profile.
1.7 Scope of Dissertation
The Warner Research Group has worked diligently over the past decade to elucidate the
chemical processes involved in CVD.

Along the way, we have pioneered the use of

sophisticated analytical techniques such as cross polarization magic angle spinning (CP-MAS)
NMR76 and inductively coupled plasma-mass spectrometry (ICP-MS)75,
characterizations of atherosclerotic plaques.

77

in elemental

The findings from these earlier studies have

afforded a better understanding of atherosclerosis. This dissertation continues this fundamental
CVD research and describes the implementation of several new research directives related to the
study of Hcy and related CVD indicators. The first chapter is a general review of topics relevant
to the research presented in this dissertation. Chapter 2 describes the exploration of molecular
interactions related to in vitro pyridoxal tetrahydrothiazine formation in order to establish an
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empirical basis for nonenzymatic Hcy clearance in the body. This topic is further evaluated in
Chapter 3, which is a report on the use of CE to monitor inhibition of N-homocysteinylationinduced protein oligomerization by pyridoxal. In addition, spectroscopic data pertaining to in
situ pyridoxal tetrahydrothiazine formation in the presence of N-Hcy-protein is presented and
discussed. Chapter 4 provides an account of our efforts to develop a plasmon resonant sensor
for plasma N-Hcy-Protein detection in serum. GNP self-assembly behavior is examined in the
presence of both unmodified and N-Hcy-protein by use of UV-vis spectroscopy and transmission
electron microscopy. More in-depth investigations of the underlying physiochemical processes
involved in plasmon resonance Hcy sensing are presented in Chapter 5. Three different types of
gold nanobioconjugates are prepared by coating colloidal gold with albumin, cytochrome c, or
serum, respectively. Plasmon resonance absorption, nanobioconjugate assembly, and protein
conformational changes are monitored. The mechanism of gold nanobioconjugate association is
also evaluated.

Chapter 6 is a discussion of the feasibility of using a hybrid organic-

immunoaffinity extraction method to enhance GC-MS analyses of PAHs in atherosclerotic heart
plaque samples.

The performance of the hybrid method is subsequently compared to a

conventional organic extraction method. Chapter 7, the final installment of this dissertation,
provides a comprehensive research synopsis as well as recommendations for future research.
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CHAPTER 2
SPECTROCHEMICAL INVESTIGATION OF PYRIDOXAL
TETRAHYDROTHIAZINE FORMATION
2.1 Introduction
Vitamin B6 (pyridoxal) is an important bioactive aldehyde cofactor that helps mediate
various enzymatic processes associated with Hcy metabolism and protein synthesis.1,

2

Alternatively, pyridoxal can undergo facile nonenzymatic reactions with both Hcy and HTL
under physiological conditions to form a stable and biologically inert pyridoxal
tetrahydrothiazine (PT) complex (Figure 2.1).3 The PT reaction is initiated by SN1 nucleophilic
substituion between the pyridoxal aldehyde group and the primary amine on either Hcy or HTL.
The reaction is subsequently completed by way of thiolate nucleophilic attack at the newly
created aldehyde carboimide, which gives a six-member thiazine ring.3, 4

Figure 2.1 Formation of pyridoxal tetrahydrothiazine via aldehyde condensation.
Since the thiazine reaction occurs spontaneously under physiological pH conditions, we
hypothesize that PT formation could serve as an auxiliary mechanism for in vivo Hcy clearance,
thereby lower blood Hcy levels and CVD risk. This premise is referred to as the PT-Hcy
sequestration and clearance hypothesis. Such a scenario has implications for inhibiting protein
homocysteinylation in individuals who are unable to clear Hcy due to congenital metabolic
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defects. The premise was initially evaluated by monitoring the spectrochemical behavior of
pyridoxal-5-phosphate in the presence of Hcy. The primary goal of this study is to gain a better
understanding of the fundamental molecular interactions involved in PT production.
2.2 Methods
2.2.1 Materials
Pyridoxal-5-phosphate, D,L-Hcy, and HTL were obtained from Sigma-Aldrich, Inc. (St.
Louis, MO) at the highest available purity. Ultra-grade tris-base and tris-hydrochloride were
obtained from Invitrogen Life Technologies (Carlsbad, CA) and Amersco (Solon, OH),
respectively. Ultra-pure water (18 MΩ resistance) was obtained from a PURELAB Ultra Genetic
(Wycombe, UK) water purification system.

All other reagents used in this work were of

analytical purity or greater.
2.2.2 Buffer and Sample Preparation
Tris-buffered saline (TBS), pH 7.4, 50 mM, was prepared according to a standard
laboratory recipe; 6.35 g tris-hydrochloride, 1.18 g tris-base, and 8.77 g sodium chloride
dissolved in 1 L of water. The pH of the buffer was subsequently adjusted to 7.4 with either
concentrated sodium hydroxide or hydrochloric acid.

The TBS buffer was degassed by

sonication for 20 min prior to use. Pyridoxal stock solutions were prepared by dissolving the
HCl salt in TBS. Hcy stock solutions were prepared fresh daily to avoid oxidation. Pyridoxal
and Hcy stock solutions were mixed directly in the cuvet to obtain the desired molar ratio.
Reaction mixtures were incubated for 1h at 37°C.

Cuvets were rinsed sequentially with

methanol, water, and the sample prior to each measurement.
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2.2.3 Instumentation
Steady-state fluorescence excitation and emission spectra were acquired in triplicate at
room temperature using a Spex Fluorolog-3 spectrofluorimeter (model FL#-22TAU3; Jobin
Yvon, Edison, NJ) equipped with a 450-W xenon lamp and R928P photomultiplier tube (PMT)
emission detector. Raw fluorescence signal was normalized to the reference PMT signal to
account for lamp intensity fluctuations. Florescence spectra were blank subtracted and corrected
for inner-filter effects when necessary. Absorption spectra were collected using a UV-Vis-NIR
spectrophotometer (model UV-3101PC) manufactured by Shimadzu (Columbia, MD). Both
fluorescence and UV absorption measurements were acquired in 10 mm2 quartz cuvets.
2.3 Calculations and Data Analysis
Primary and secondary inner-filter corrections for fluorescence spectra were performed
when necessary using equation 1;5

Fcorr = Fobs 10

⎡ ODex+ODem ⎤
⎢
⎥
2
⎣
⎦

;

(1)

where Fcorr is corrected fluorescence intensity, Fobs is observed fluorescence intensity, ODex and
ODem are the optical densities for the excitation and emission wavelengths respectively.
Molecular interaction between Hcy and pyridoxal was assessed using the BenesiHildebrand method6, 7.

The Benesi-Hildebrand method can be used to obtain binding kinetics

information from fluorescence data. For example, equation 2 describes 1:1 stoichometry for a
thiazine complex.

pyridoxal + Hcy ⇔ thiazine complex
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(2)

Thus, the association constant for equation 2 is represented by equation 3;

K thiazine complex

=

[ thiazine complex n ]
[ pyridoxal ][ Hcy ]n

(3)

;

where [thiazine complex], [pyridoxal], and [Hcy] are the equilibrium concentrations of the
product and reactants, respectively. The stoichometry of the system is denoted by n, which is
continuously varied in the experiment such that the [pyridoxal] remains constant and [Hcy] >>
[pyridoxal]. The relationship between fluorescence intensity and [Hcy] is given by equation 4;

1
1
1
=
+
F − F0
K ( F∞ − F0 )[ Hcy ]0n
F∞ − F0

(4)
;

where F is the fluorescence intensity of pyridoxal in the presence of Hcy, F0 is the fluorescence
intensity of pyridoxal in the absence of Hcy, F∞ is the fluorescence intensity observed for
pyridoxal associated with Hcy, [Hcy]0 is the initial concentration of Hcy and K is the association
constant for the system. K is empirically determined by obtaining the slope of the line resulting
from plotting

1
F − F0

versus

1
[ Hcy]0n

.

The stoichometry of the system is empirically

determined by substituting different values for (n) into the equation of the line. For instance, nvalues of 1, 2, and 3, represent stoichometries of 1:1, 1:2, and 1:3, respectively. The best linear
fit (R2) is obtained when the correct stoichometric value is chosen.
2.4 Results and Discussion
2.4.1 UV-visible Spectroscopy Studies of Thiazine Formation
The spectrochemical behavior of pyridoxal was evaluated in the presence of Hcy under
physiological pH conditions using UV-vis spectroscopy (Figure 2.2). Pyridoxal exhibits two
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broad and intense absorption bands at ~277 and 414 nm. The addition of Hcy to the pyridoxal
solution caused these peaks to diminish while a new absorption band emerged at 330 nm to
indicate PT formation. The arrows in the figure indicate the change in UV-vis absorption due to
PT in solutions containing 1:0, 1:0.5, 1:1, 1:2, 1:5, and 1:10 [pyridoxal]:[Hcy]n, respectively.
The reaction was found to be stable and irreversible under the conditions used in this study.

Figure 2.2 UV-Vis absorption spectra of solutions containing pyridoxal in presence of
increasing concentrations of Hcy.
2.4.2 Fluorescence Characterizations
Hcy-dependent enhancements in pyridoxal fluorescence intensity were initially
monitored at 414 nm while scanning excitation wavelength. The resultant spectra indicate that
pyridoxal fluorescence is proportional to PT absorption, which was previously monitored at 330
nm (Figure 2.3a). Normalized excitation spectra are shown in Figure 2.3b to illustrate the
magnitude of the shift (~10 nm) caused by increased PT production. Corresponding emmision
spectra were acquired by excitation at 330 nm (Figure 2.3c). The emission spectra illustrate
fluorescence enhancements at 400 nm, which are consistent with PT formation.
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a)

b)

c)

Figure 2.3 Fluorescence spectra of PT formation.
The Stern-Volmer equation was applied to both the uncorrected and inner-filter corrected
emission data in order to assess fluorescence quenching as a function of Hcy concentration.
Figure 2.4 is a plot of F0/F-1 versus [Hcy], where F0 is the fluorescence -intensity of pyridoxal in
the absence of Hcy, and F is the observed fluorescence intensity for pyridoxal in the presence of
increasing concentrations of Hcy. The correlation coefficients obtained for uncorrected and
corrected Stern-Volmer plots were 0.941 and 0.950, respectively. However, it is readily apparent
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that both data sets are non-linear, which may indicate non-Stern-Volmer behavior. The most
likely reason for these inconclusive results is that the experimental conditions used in this study
do not yield 1:1 association, which is a precondition for use of the Stern-Volmer relationship.

Figure 2.4 Stern-Volmer plot showing trend for uncorrected (solid line) and corrected (dotted
line) PT fluorescence emission.
Next, the Benesi-Hildebrand treatment was applied to the PT system to estimate binding
stoichometry. In this exercise,

1
1
was plotted versus
; where n represents the
F − F0
[ Hcy]0n

stoichometry of the system. Benesi-Hildebrand plots for the PT system are shown in Figure 2.5.
The coefficient of correlation obtained for n = 1, 2, and 3 were 0.994, 0.998, and 0.987,
respectively. The stoichometric value, n = 2, gave the best fit and suggests 1:2 stoichometry for
the PT system. This may help explain the previously observed deviation from the Stern-Volmer
behavior. As previously discussed, PT formation is usually the result of 1:1 association, which is
not supported by the Benesi-Hildebrand data. One possible explanation for this discrepancy is
that pyridoxal-5-phosphate, not pyridoxal, was used in these studies. Consequently, a second
Hcy molecule could associate with the phosphate group (PO4-) due to electrostatic interactions,
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resulting in 1:2 stoichometry. This scenario becomes especially probable when pyridoxal-5phosphate is in the presence of excess Hcy.

Figure 2.5 Benesi-Hildebrand plots for PT formation.
It is also important to consider the biochemical fates of pyridoxal and pyridoxal-5phophate. Pyridoxal-5-phosphate version is the preferred ingredient in vitamin supplements for
practical reasons including ease of synthesis-extraction and long shelf-life. However, the body
possesses mechanisms for converting between the two forms of pyridoxal based on biological
need. Thus, it is likely that pyridoxal and the phosphate-5-phosphate coexist in vivo.
2.5 Conclusions
In summary, we have confirmed that pyridoxal-5-phophate readily interacts with Hcy and
HTL under physiological pH and temperature conditions. Initial attempts to characterized the
molecular interactions involved in PT formation using the Stern-Volmer yielded inclusive
results.

Hence, the Benesi-Hildebrand treatment was applied to system to assess the
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stoichometry of the PT reaction. Benesi-Hildebrand analysis indicated the possibility of 1:2
stoichometry, which appeared to contradict the 1:1 mechanisms reported in the literature. The
discrepancy in stoichometry was attributed to differences in the chemical forms of pyridoxal
used in the experiment. Indeed non-phosphorylated pyridoxal undergoes 1:1 association with
Hcy. However, pyridoxal-5-phosphate was used in this study. It was also found that pyridoxal5-phosphate may bind two molecules of Hcy simultaneously, via Schiff base linkage and via
electrostatic biding at the phosphate group. This preliminary report provides empirical support
the PT-Hcy sequestration and clearance hypothesis, but further study is needed to determine if
PT formation can occur in the presence of proteins and other biomolecules. In light of this goal,
the TBS buffer system will be replaced with phosphate buffered saline, which is considered by
most to be more biologically relevant.

Phosphate is also the preferred buffer for protein

experiments.
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CHAPTER 3
CAPILLARY ELECTROPHORETIC SCREENING FOR INHIBITION OF
HOMOCYSTEINE THIOLACTONE- INDUCED PROTEIN OLIGOMERIZATION
3.1 Introduction
The material presented in this chapter is reproduced in part with permission from
Analytical Chemistry, 2007, volume 79, pages 8249 -8256; Gates, A. T.; Lowry, M.; Fletcher, K.
A.; Merugeshu, A.; Rusin, O.; Robinson, J. W.; Strongin, R. M.; Warner, I. M.; Rapid
Electrophoretic Screening of Homocysteine Thiolactone-Induced Protein Oligomerization Using
Cationic Polyelectrolyte-Coated Capillaries, which was copyrighted in 2007 by the American
Chemical Society.
Increased in vivo HTL production is believed to initiate vascular damage and the
formation of early atherosclerotic lesions.1,

2

The proposed mechanism for post-translational

protein modification by HTL involves the site-specific acylation of ε-amino groups on lysine
residues to yield a thiolated species known as N-Hcy-protein (Scheme 3.1).3, 4 If left uninhibited,
individual N-Hcy-protein molecules in proximity to each other may undergo spontaneous
intermolecular disulfide bonding to yield aggregate species.3, 5 HTL-induced protein aggregation
(HTPA) may bring about several unfavorable physiological effects. In particular, aggregated
proteins often exhibit decreased biological activity, decreased solubility,3 and increased
immunogenicity.6 As one would expect, the extent of physiological dysfunction caused by
protein aggregation varies among the many different types of proteins. Empirical evidence of
HTPA has been reported for LDL,7 cyt c, and human serum protein3 under physiological
conditions. Moreover, a recent clinical study reported the discovery of higher than normal levels
of Hcy thiolactone-modified proteins in individuals with coronary heart disease.8
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Scheme 3.1 Homocysteine thiolactone-induced protein modification. Under physiological pH
conditions Hcy thiolactone can preferentially acylate protein lysine residues at ε-amino groups to
yield N-Hcy-protein
Given the potential clinical significance of HTPA as an indicator of cardiovascular and
neurovascular diseases, the development of rapid primary screening methods for HTPA is of
importance. SDS-PAGE is perhaps the most widely used technique for a variety of routine
protein screening applications. Although SDS-PAGE is often very effective for the separation of
most protein aggregates, lengthy analysis times and tedious staining procedures are a hindrance
to its use in most high throughput clinical screening applications. In addition, SDS-PAGE is
generally considered to be semi-quantitative, limiting its utility in quantitative applications. In
contrast, capillary electrophoresis (CE) equipped with UV detection is quantitative and generally
provides sufficient sensitivity without the necessity for dye-staining or radioisotope labeling as is
often the case for SDS-PAGE.
With CE instrumentation becoming more common place in laboratories, capillary
electrophoretic separation can be practical alternative to conventional SDS-PAGE for clinical
and pharmaceutical-type protein separations.9-11 Further, reports in the literature of CE-based
protein separation techniques have steadily increased over the past decade.12-15 This trend is due
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in part to the ongoing development of polyelectrolyte coatings, which provide can provide an
effective remedy for protein-wall adsorption.16 Our laboratory has established the usefulness of
various micellar coatings as stationary phases for capillary electrophoretic chromatography.17-22
Our more recent studies have employed amino acid-functionalized molecular micellar stationary
phases for open tubular-capillary electrochromatography.

These coatings allow for facile

column fabrication and exceptional separation performance for both chiral and achiral
analytes.18-22
Herein, we report the development of a rapid capillary electrophoretic method for the
quantitative assessment of HTPA.

Capillaries coated with poly (diallyldimethylammonium

chloride) (PDADMAC) were used to minimize protein-wall adsorption. Hcy thiolactone and cyt
c were reacted in vitro to induce protein aggregation.

The resultant mixture containing

monomeric and aggregate species was separated using CE equipped with UV detection. We also
demonstrate a short-end injection method for in vitro pre-clinical HTPA inhibition screening.
3.2 Methods
3.2.1 Materials
Bovine cyt c, L-HTL, pyridoxal-5-phosphate hydrogen chloride, streptomycin sulfate,
SDS-PAGE protein molecular weight markers, PDADMAC 20% w/v water solution (Mw
200,000-350,000), tris (hydroxymethyl) aminomethane (TRIS), and all other reagents used for
preparing reaction and background electrolytes were obtained from Sigma-Aldrich (St. Louis,
MO) at the highest purity available and used without further purification. Ultra pure water (18.2
MΩ) was obtained by use of an Elga model PURELAB Ultra™ water filtration system.
3.2.2 Preparation of Protein Reaction Mixtures
Protein reaction mixtures were prepared by dissolving Hcy thiolactone (2.5 mM) and cyt
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c (10 mg/mL) in pH 7.4, 100 mM sodium phosphate, 0.2 mM ethylenediaminetetraacetic acid
(EDTA) buffer, according to procedures previously reported by Jakubowski.3 It was found that
12 h (at 25 °C) was the approximate minimum time required for appreciable aggregate formation
to occur in the protein reaction mixture without protein precipitation. Accordingly, samples used
for CE studies were reacted at 25 °C while mixing for 12 h to obtain the protein aggregate
mixture. The modification reaction was quenched by removing the protein from the reaction
mixture using a Millipore (Bedford, MA) Amicon Ultra, 10,000 kDa molecular weight cut-off
(MWCO) filter device centrifuged at 3600 rpm for 20 min or until completion. The protein
retentate was rinsed with 2 mL of the reaction buffer to remove nonspecifically bound material.
Protein and filtrates were stored at -20 °C for no more than one week. Unless otherwise
indicated, the protein retentates were reconstituted in either the background electrolyte (50 mM
pH 8.5 tris buffer). All protein and buffer solutions were passed through a 0.45 μm nylon
syringe filter prior to separation by CE. Protein reaction mixtures for HTPA inhibition studies
were prepared and treated in the same manner as described above, except the appropriate
quantity of pyridoxal-5-phosphate stock solution was simultaneously added with the HTL and
protein solution to obtain the desired component concentrations.
3.2.3 SDS-PAGE Protocol
SDS-PAGE experiments were conducted using a Mini-Protean 3™ gel electrophoresis
unit with 1000 V power supply. Polyacrylamide gels (4-20%) were purchased from Bio-Rad
(Hercules, CA).

The sample buffer was prepared by combining 0.2 mL of 0.5% (w/v)

bromophenol blue, 2.0 mL of 10% (w/v) SDS, 2.5 mL of glycerol, 1.25 mL of pH 6.8, 0.5 M
TRIS hydrochloride, and 3.55 mL bioscience grade water to obtain a total volume of 9.5 mL.
Protein samples were diluted to 0.1 μg/mL with sample buffer and thermally denatured under
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non-reducing conditions at 95 °C for 5 min prior to SDS-PAGE analyses. The stock running
buffer was prepared by dissolving 15.15 g tris-base, 72 g glycine, and 10.0 g SDS in bioscience
grade water to obtain a final volume of 1L and working pH of 6.8. The stock run buffer was
diluted 10-fold to obtain the final running buffer. SDS-PAGE separations were run at 200 V for
30 min at room temperature followed by staining for 1 h with SimplyBlue SafeStain Coomassie
G-250, obtained from Invitrogen (Carlsbad, CA). The gels were destained water for at least 12 h
to obtain optimum band contrast. A Kodak Gel Logic 100 digital imaging system purchased
from Eastman Kodak Company (Rochester, NY) was used for gel imaging.
3.2.4 Instrumentation
A Beckman Coulter (Fullerton, CA) P/ACE MDQ capillary electrophoresis system
equipped with a photodiode array detector was used for separations. Fused-silica capillaries (50
μm i.d.) were purchased from Polymicro Technologies (Phoenix, AZ) and cut to 32 cm total
length, having an effective length of 22 cm.

Capillaries were modified with 20 mg/mL

PDADMAC dissolved in pH 8.5, 50 mM tris buffer. A capillary coating was deposited over a 12
h period using alternating rinse cycles of PDADMAC solution at high pressure (20 psi) for 5 min
and low pressure (0.5 psi) for 120 min as previously described elsewhere.23 After coating,
capillaries were rinsed with the background electrolyte at 5 psi for 40 min to remove excess
PDADMAC. Electrokinetic injections and separations were performed under reversed polarity
conditions at 25 ± 1 °C. The capillary was rinsed with the background electrolyte for 2 min at
5.0 psi prior to each run. Separations were simultaneously monitored from 200 to 320 nm using
a photodiode array detector.
3.2.5 Data Analysis
Data acquired at 200 nm were exported to a spreadsheet and fit to Gaussian peaks.
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Migration time, peak width, and peak area determinations for CE separations were computed
based on the best fit data.
Resolution (Rs), full width at half-height (FWHH), and number of theoretical plates (N)
were calculated using the following equations:

Rs =

( t r , 2 − t r ,1 )
1
2

( w1 + w 2 )

,

(1)

FWHH = w 1 = 2.35 σ ,

(2)

2

⎛
⎜ t
N = 554 ⎜ r
⎜w1
⎝ 2

2

⎞
⎟
⎟ ,
⎟
⎠

(3)

where tr,1 and tr,2 are the migration times for the earlier and later eluting peaks, respectively; w is
peak width at baseline for each peak, w 1 is FWHH, and σ is the standard deviation of the
2
Gaussian peaks.
Short-end injection is a technique used in CE to obtain shorter analysis times by
circumventing instrumental limitations on minimum capillary length.24-26

Short-end injections

and separations were performed by applying voltage in reversed polarity with reference to the
outlet in order to obtain EOF towards the detection window, resulting in an effective capillary
length of 10 cm with no change in total capillary length (32 cm). Short-end electrokinetic
injections were performed from the outlet-end of the capillary using 5 kV for 7 sec.
3.3 Results and Discussion
3.3.1 Characterization of the Protein Reaction Mixture
As previously discussed, HTPA is initiated by acylation of protein lysine residues by
HTL. Consequently, the degree of reactivity of Hcy thiolactone toward a given protein is largely
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dependent on lysine content. Cyt c is a ubiquitous, basic metalloprotein found associated with
the mitochondria of most cells.

Bovine cyt c was selected as the model protein for

demonstrating the proposed method because it is relatively small in size (MW 12,327 kDa),
highly soluble, and has a relatively high lysine content (20% w/w),27 making it susceptible to
modification by HTL and the subsequent aggregation of N-Hcy-protein species.
HTL-induced cyt c aggregation was previously demonstrated by Jakubowski using SDSPAGE with radioisotope imaging.3 Similarly, SDS-PAGE analysis was used initially to confirm
aggregation in the protein reaction mixtures prior to proceeding to CE analyses. As expected,
monomer and aggregate bands were visible in gel images after dye staining with coomasie blue
(Figure 3.1a). The three relatively broad bands were identified as monomeric (I), dimeric (II),
and trimeric (III) cyt c species as determined by comparison with SDS-PAGE protein molecular
weight markers. Treatment of the same protein reaction mixture with 5 mM dithiothreitol
(DTT), a disulfide reducing agent, eliminated aggregate bands (data not shown). Additional
characterization of the protein reaction mixture using MALDI TOF-MS (Figure A.1 in Appendix
A) also detected monomer and aggregate species in the protein reaction mixture having signal
intensities comparable with those observed with SDS-PAGE and are consistent with covalently
bonded cyt c aggregation due to intermolecular disulfide formation.
Protein-wall adsorption can be especially problematic for capillary zone electrophoresis
separations of proteins. The surface of bare fused silica capillaries is not usually conducive to
separation of proteins because of electrostatic attraction between the anionic deprotonated silanol
groups and the positively charged protein residues. Therefore, it is often necessary to modify the
silica surface with an appropriate coating to reduce protein adsorption.

The cationic

polyelectrolyte PDADMAC was selected for separation of the protein reaction mixture
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containing cyt c (pI~10), which is also cationic under the experimental condition used in this
study.

Figure 3.1 Representative electrophoretic separations of protein reaction mixtures. a) gel
separation showing bands corresponding to I, II, and III c, b) electropherogram of non-denatured
protein mixture, c) electropherogram for thermally denatured sample and plot of electrophoretic
migration time versus species molecular weight (inset).
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3.3.2 Preliminary Evaluation of Protein Separation
The separation of proteins using PDADMAC-modified capillaries can be greatly affected
by polymer molecular weight and column coating conditions. In that regard, it has been shown
that capillary coating procedures that use a combination of high ionic strength and high
molecular weight PDADMAC provide enhanced surface coverage and charge inversion.23 In
addition, it has been proposed that larger molecular weight PDADMAC polymers may facilitate
the formation of “loop and tail” structures on the capillary surface, with which protein analytes
may interact.23 For that reason, PDADMAC having a molecular weight range of 200-350 kDa
was chosen as the wall coating in this work.
Figure 3.1b is a typical electropherogram resulting from the separation of native protein
reaction mixtures using PDADMAC coated capillaries. The increased sensitivity provided by
UV detection allowed for the detection of two additional peaks attributed to tetrameric (IV) and
pentameric (V) species that were not visible in the SDS-PAGE image shown in Figure 3.1a.
The analysis time for the separation shown in Figure 3.1b was less than 8 min, including the
rather significant tailing of the monomer peak. The migration order was determined to be
tetramer (IV), trimer (III), dimer (II) and monomer (I), respectively. We note that migration time
for modified protein species was inversely related to molecular weight as is expected for the
reversed polarity conditions used in these studies.
3.3.3 Effect of Protein Denaturation on Separation Performance
Separations performed with non-denatured samples tended to result in peak tailing and
poor peak shape. The prominent asymmetric features observed for the monomer and dimer
peaks in native protein reaction mixtures are primarily attributed to protein conformation effects.
Protein conformation effects are caused by the various shapes which proteins may assume under
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native conditions due to their secondary and tertiary structure. Oligomeric protein species, such
as those produced by HTPA, may also exhibit some degree of quaternary structure. Collectively,
these factors may contribute to undesirable electrophoretic separation performance including
band broadening and poor peak shape. Consequently, it is sometimes necessary to treat protein
samples with denaturing agents prior to electrophoretic separation to minimize conformation
effects. For example, protein denaturation for SDS-PAGE is typically achieved by boiling the
protein mixtures in a high ionic strength buffer that contains the anionic surfactant SDS and
reducing agents such as dithiothreitol or 2-mercaptoethanol. This approach is not compatible
with basic proteins or the cationic polyelectrolyte coating used in this study. Hence, SDS was
omitted from sample pretreatment to preserve the cationic character of cyt c. Disulfide reducing
agents were also excluded from sample preparation to avoid the unintentional cleavage of
intermolecular disulfide bonded aggregates. Instead, samples were thermally denatured under
non-reducing conditions in the background electrolyte by heating at 90 °C for 5 min prior to
analysis. Figure 3.1c illustrates the substantial improvement in peak symmetry observed for
thermally denatured protein samples. It is also noted that tailing of the monomer peak is
significantly reduced.

There was also marked improvement in the irregular peak shape

previously observed for the dimer peak under native conditions.

Additionally, thermal

denaturation allowed for better detection of a minor pentameric component. The analysis time
for the denatured sample was less than 7 min. These results suggest that thermal denaturation
alone is sufficient pretreatment for this study.
The inset in Figure 3.1c shows a plot of protein molecular weight versus migration time
generated from the average of five consecutive runs of thermally denatured samples containing
species I-V. Note that the x-axis was generated based on integer multiples of the molecular
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weight for monomeric bovine cyt c as reported by the manufacturer. Migration times determined
from best fit data exhibited good precision, having standard deviations less than 0.5% for all
detected species.
The analysis of protein samples denatured with organic solvents including methanol,
ethanol, acetonitrile, and acetone was also evaluated. In general, the use of volatile organic
solvents greatly complicated sample preparation and CE analyses. Relatively high organic
solvent content, around 1:1 buffer/organic solvent, was usually required to achieve results
comparable to thermally denatured samples. However, the addition of organic solvent to the
samples often caused appreciable protein precipitation, which often resulted in erratic baselines
and poor separation reproducibility (data not shown). In addition, protein precipitation also
caused frequent column blockages resulting in a reduction in column lifetime. For these reasons,
organic solvents were also excluded from sample preparation procedures.
3.3.4 Voltage Optimization
The effect of applied voltage on migration time and peak efficiency was investigated for
the separation of protein reaction mixture components using 21 cm effective length columns.
Figure 3.2 illustrates the effect of a range of applied voltages on the separation of cyt c
aggregates using a freshly prepared capillary. As expected, the shortest analysis time (2.33 min)
was obtained at -15 kV. However, voltages higher than -15 kV often resulted in unstable current
and poor reproducibility. In addition, separation efficiency improved with increasing voltage as
indicated by a roughly 2-fold improvement in peak width observed from -8 to -15 kV (data not
shown). Resolution also improved significantly with increasing voltage.

Resolution (Rs)

between the monomer and dimer peaks at -8 kV and -15 kV were 1.04 and 1.20, respectively.
Evaluation of these data suggests that peak efficiency was limited primarily by longitudinal band
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broadening under the conditions used for these studies.

Figure 3.2 Effect of applied voltage on CE separations of protein reaction mixture components:
a) electropherograms acquired at -15, -12, -10, and -8 kV. Separations were performed using a
freshly prepared column.
3.3.5 Short-End Injection Method
Initial studies for this work were conducted using capillaries with a total length of 32 cm
(21 cm effective capillary length). In order to obtain more rapid separations, the effective length
of the capillary was decreased to 10 cm by injecting and separating from the outlet-end of the
capillary. Figure 3.3 shows a typical short-end electropherogram where separation of the protein
reaction mixture containing species I-V was achieved in less than 70 sec. Although there was
minor deterioration in peak shape observed for the tetrameric and pentameric species, overall
short-end separation performance was acceptable.
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Figure 3.3 Electropherogram of thermally denatured protein reaction mixture containing cyt c
species I-V separated in less than 70 sec using short-end injection. Separation performed with an
applied voltage of 8kV (22 μA current) and a 50 μm i.d., 32 cm total length, 10 cm effective
length capillary column.
In order to assess the stability of the short-end injection method, reproducibility and
electrophoretic efficiency were evaluated for 5 successive runs without regenerating the
PDADMAC coating. Various column performance values are provided in Table 3.1. Run-torun reproducibility for migration times was generally excellent, having RSD values < 0.5% for
all monomer, dimer, and trimer peaks. Good precision was observed for peak area values,
indicating reproducible injection volumes and near ideal eletrophoretic behavior with respect to
minimized analyte-wall adsorption. The relatively high number of theoretical plates (N), in
some instances approaching one million, indicate exceptional column efficiency for separating
monomer and aggregate species. In addition, satisfactory column-to-column reproducibility was
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also achieved as indicated by RSD values < 1% (n = 10) for migration times obtained from 5
consecutive runs performed with two different PDADMAC coated capillaries. Overall, shortend injection provided satisfactory separation performance for the analysis of the protein reaction
mixture in significantly less time than normal injection conditions.
Table 3.1. Separation performance and reproducibility statistics for short-end CE
separations of protein reaction mixture.*

Protein Mixture
Component

Migration
Time, min

Peak Area

Number of
Theoretical Plates (N)
× 105

Monomer (I)

1.92 (0.28)

220.54 (3.90)

8.55 (3.24)

Dimer (II)

1.75 (0.42)

63.76 (4.38)

5.75 (5.93)

Trimer (III)

1.62 (0.48)

15.08 (5.77)

7.70 (6.73)

*Migration time, peak area, and number of theoretical plates (N) values calculated for
successive runs (n=5) without regeneration of the poly (diallyldimethylammonium
chloride) (PDADMAC) coating. Percent relative standard deviation (%RSD) values are
given in parentheses. Separations performed using 8 kV applied voltage.
3.3.6 Oligomerization Inhibition Studies
Pyridoxal-5-phosphate (PLP) is the aldehyde-functionalized cofactor derivative of
vitamin B6. The antiatherogenic properties of PLP for lowering plasma Hcy levels and risk of
cardiovascular disease are documented in the medical literature.28,
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However, very little is

known about the effect of PLP on HTPA. Recently reported mechanistic studies suggest the
possibility of pyridoxal tetrahydrothiazine formation via condensation of Hcy thiolactone with
PLP as a means of neutralizing Hcy thiolactone in vivo.30 Similarly, we propose that in situ
pyridoxal tetrahydrothiazine formation could possibly disrupt Hcy thiolactone-induced protein
modification in vitro, thereby inhibiting HTPA. To further investigate this hypothesis, the
previously optimized short-end CE method was applied to the evaluation of HTPA inhibition.
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Figure 3.4 Results for aggregation inhibition study represented as a) percent of total protein peak
area determined by integration of best fit data; and b) percent change for respective mixture
component peak areas normalized to an experimental control versus pyridoxal-5-phosphate
concentration.
Representative results for protein reaction mixtures in the presence of PLP are
summarized in Figure 3.4. Mixture components are denoted as monomeric, I ( ); dimeric, II
trimeric, III (

); and tetrameric, IV (

); respectively. The total of aggregates ( ) is obtained

by taking the sum of the respective contributions of mixture components II-IV.

The

experimental control sample (0 mM PLP) was found to contain cyt c species I-IV, in which
aggregates (II-IV) represented 77.12 ± 1.72% of total cyt c (Figure 3.4a). All aggregate species
decreased with increasing concentrations of PLP to a minimum value of 55.58 ± 1.42% observed
at 2.5 mM PLP (Figure 3.4b). At the same time, there was a complementary increase in the
monomeric species with increasing concentrations of PLP. The trimer species exhibited the
greatest change of total protein (-11.79 ± 0.94%) followed by the dimer (-8.32 ± 1.60%). The
changes observed for the minor tetrameric component with respect to the experimental control
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were within experimental error. Figures 3.5a and 3.5b show representative electropherograms
acquired for protein reaction mixtures treated with 0.25 and 2.5 mM PLP after 24 h. Note the
overall reduction in aggregate species for the sample treated with 2.5 mM PLP. Comparable
inhibition trends were also visible in SDS-PAGE slab gels (Figure A.2 in Appendix A).
Collectively, these results suggest that in vitro HTPA is effectively inhibited by PLP.

Figure 3.5 Representative short-end CE electropherogram resulting from the separation of the
protein reaction mixture treated with a) 0.25 mM pyridoxal-5-phosphate and b) 2.5 mM
pyridoxal-5-phosphate, respectively. Separation performed using an applied voltage of 8kV (22
μA current) and a 50 μm i.d., 32 cm total length, 10 cm effective length capillary column.
Analysis times for PLP-treated samples separated under optimized conditions were
typically around 1.5 minutes, approximately twice as long as those obtained for untreated
samples. It is probable that PLP, which is anionic under experimental conditions, binds nonspecifically with the protein resulting in decreased cationic character and increased electrostatic
interaction between the protein and the PDADMAC coating. Despite efforts to thoroughly rinse
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the protein prior to analysis, some PLP remained associated with the protein as was indicated by
the characteristic reddish-orange color of the reaction solutions. Nevertheless, more than
adequate resolution was obtained to achieve a quantitative analysis.
In situ pyridoxal tetrahydrothiazine formation was initially proposed as the mechanism
for HTPA inhibition of PLP.

Therefore, efforts were made to determine if pyridoxal

tetrahydrothiazine could be detected in the protein reaction mixtures. Protein reaction mixtures
(500 uL) containing 10 mg/mL cyt c, 2.5 mM Hcy thiolactone, and the desired quantity of PLP
were prepared as previously described and allowed to react for 12 h. For comparison, a set of
control reaction mixtures containing identical amounts of PLP and Hcy thiolactone (without
protein) was also prepared. The reaction mixtures were passed through a 10 kDa MWCO
centrifugation filter to remove the protein. Reaction mixture filtrates and control samples were
diluted 10-fold and analyzed using UV-Vis spectroscopy. Individual reaction components, PLP
and pyridoxal tetrahydrothiazine, were monitored at 390 nm and 330 nm30, respectively.
Tetrahydrothiazine formation in the control reactions increased linearly with PLP
concentration (Figure A.3a in Appendix A). In situ tetrahydrothiazine formation in protein
filtrates also increased in response to increasing PLP concentration until a maximum was
reached at 1.88 and 2.5 mM (Figure A.3b in Appendix A). The maximum absorption for the
tetrahydrothiazine product for protein samples was approximately 2-fold less than the maximum
observed for the control reaction. This reduction in product absorption for filtrate samples is
likely the result of non-specific binding of PLP and/or pyridoxal tetrahydrothiazine to the
protein. The presence of cyt c-bound PLP was indicated by a subtle color change in the retentate
from red to reddish-orange. In situ tetrahydrothiazine production was also limited to a lesser
extent by N-Hcy-protein formation. Overall, this result suggests that in situ tetrahydrothiazine

56

formation inhibits HTPA in vitro.
3.4 Conclusions
We have shown that CE with UV detection provides a practical alternative to semiquantitative SDS-PAGE for monitoring homocysteine thiolactone-induced protein aggregation.
Capillaries coated with PDADMAC provided good column stability and reproducibility. Under
optimized conditions, short-end injection typically allowed the separation of thermally denatured
protein reaction mixtures in less than 70 sec.
In this study we have also demonstrated rapid primary HTPA inhibition screening with
analysis around 1.5 min, which is a considerable improvement over the hour timeframe typically
required to perform a comparable SDS-PAGE analysis. We have shown that PLP effectively
inhibits HTPA in vitro. This inhibitory effect is attributed to in situ formation of pyridoxal
tetrahydrothiazine, which was detected in the protein samples treated with PLP.

This

preliminary finding is congruent with mechanistic studies previously reported by Jakubowski
that proposed pyridoxal tetrahydrothiazine formation as a possible mode of neutralizing Hcy
thiolactone in the body. However, further study is needed to determine if inhibition of HTPA by
PLP is a physiologically relevant phenomenon. Future work may include the evaluation of
various other polyelectrolyte coatings and an expanded field of aggregate inhibitor compounds.
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CHAPTER 4
GOLD NANOSENSOR FOR COLORIMETRIC DETECTION OF N-HCY-PROTEIN
4.1 Introduction
The material presented in this chapter is reproduced in part with permission from
Langmuir, 2008, volume 24, pages 4107-4113; Gates, A. T.; Fakayode, S. O.; Lowry, M.;
Ganea, G. M.; Murugeshu, A.; Robinson, J. W.; Strongin, R. M.; Warner, I. M.; Gold
nanoparticle sensor for homocysteine thiolactone-induced protein modification, which was
copyrighted in 2008 by the American Chemical Society.
The emergence of HTL-induced protein modification (HTPM) as a CVD indicator has
created a need for new detection methods for N-Hcy-protein. Our laboratory has contributed to
the development of several organic dye-based colorimetric and fluorimetric sensors for the
detection of various amino thiol disease biomarkers, including Cys and Hcy.1-4 Several of these
sensors show promise for amino thiol detection in human blood plasma. We have also reported
the use of redox indicators for electrochemical detection of glutathione, another important amino
thiol biomarker.5 Our recent work has focused on exploring new detection schemes and
strategies for investigating the physiochemical properties of N-Hcy-protein. For example, we
reported the development a rapid capillary electrophoresis (CE) method for separating mixtures
containing oligomeric N-Hcy-protein derived from in vitro modified cytochrome c. This CE
method was successfully applied to monitoring the inhibition of HTL-induced protein
oligomerization via in situ pyridoxal tetrahydrothazine formation.6
Separations techniques such as TLC7 and HPLC8 have also been employed to quantify NHcy-protein, but few specific detection schemes have been reported.

Enzyme linked

immunosorbent assays (ELISAs) are perhaps the most commonly used affinity technique for N60

Hcy-protein determination.9, 10 ELISAs are a highly sensitive and versatile format that can be
configured to generate either a colorimetric or fluorimetric response. Another advantage of
ELISA is the wide commercial availability of 96-well plate kits, which provide a user-friendly
interface that is amenable to high throughput applications. Unfortunately, the development of
ELISA kits for N-Hcy-protein has been hampered by the lack of commercially available
antibodies.
Plasmon resonant sensors provide an elegant option for N-Hcy-protein detection. In
particular, GNP-based plasmon resonant biochemical sensors exploit biomolecular interaction in
order to stimulate nanoparticle self-assembly.

It is often necessary to functionalize the

nanoparticles with affinity ligands in order to achieve the desired specificity.11-13 However, thiol
detection applications do not necessarily require the use of functionalized nanoparticles because
gold is intrinsically thiol reactive. For instance, citrate-capped GNPs have been successfully
employed as colorimetric sensors for various amino thiols including Hcy14, cysteine15, and
glutathione.15

Amino thiols tend to readily adsorb onto the surface of colloidal gold via

chemisorption interactions.

Plasmon resonance thiol sensing has been shown to occur via

noncovalent electrostatic-type interactions between the amino and carboxylic acid groups.14, 15
Herein, we report the use of citrate-capped colloidal GNPs as a sensor for HTPM.
Scheme 4.1 illustrates the proposed mechanism for the colorimetric GNP sensor. In the presence
of unmodified protein, the nanoparticles interact in a nonspecific manner with individual protein
molecules but remain randomly dispersed throughout the protein solution. As a result, the sensor
solution retains the characteristic red color of dispersed colloidal GNPs.

In contrast, the

nanoparticles bind with the HTL-modified proteins via chemisorption-type binding (Au-S-R),
thereby facilitating nanoparticle assembly via cross-linking. Nanoparticle assembly is further
stabilized by intermolecular disulfide bonding (R-S-S-R) between N-Hcy-protein species. The
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scale bars are shown to emphasize the relative difference in interparticle distances for dispersed
and assembled GNPs, respectively. UV-Vis absorption spectroscopy and transmission electron
microscopy (TEM) were employed to investigate the assembly behavior of colloidal gold
nanoparticles in response to N-Hcy-protein. To the best of our knowledge, direct colorimetric
detection of serum N-Hcy-protein using GNPs has not been previously reported.

Scheme 4.1 Proposed colorimetric GNP sensor for HTL-induced protein modification.
4.2 Methods
4.2.1 Materials
L-Hcy thiolactone hydrogen chloride, hydrogen tetrachloroaurate trihydrate, trisodium

citrate, EDTA, and all other reagents used for the preparation of buffer and serum protein
solutions were obtained from Sigma-Aldrich (St. Louis, MO) at the highest purity available and
used as received. Ultra pure water (18.2 MΩ) was obtained from an Elga model PURELAB
Ultra water filtration system.
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4.2.2 Synthesis of Gold Nanoparticles
Citrate-capped GNPs ca.13 nm diameter were synthesized using the well-known
Turkevich-Frens method.16, 17 Briefly, a solution of hydrogen tetrachloroaurate trihydrate was
prepared in water and heated to reflux while stirring, followed immediately by the addition of a
40 molar excess of freshly prepared trisodium citrate-water solution, which initiated the
reduction of the hydrogen tetrachloroaurate trihydrate. The aurate-citrate solution was allowed
to reflux for approximately 25 min or until completion of the redox reaction as indicated by a
change in solution color from faint yellow to dark red. The excess citrate in solution creates a
negatively charged surface on the GNPs, thereby minimizing nonspecific GNP aggregation postsythesis.17 The resultant GNP solution was allowed to cool to room temperature prior to storage
in an amber glass bottle. Aurate (1.0 mM) was reduced in 40mM citrate resulting in a GNP
stock solution of 1.0 mM, assuming complete reduction of the gold. GNP solutions were
purified using a 0.1 μm polyetrafluoroethylene syringe filter devices. Nanoparticle size was
confirmed using dynamic light scattering (DLS) and transmission electron microscopy (TEM).
4.2.3 Preparation of Protein Homocystamide
The N-Hcy-protein stock solutions used in this study were prepared using procedures
similar to those previously reported by Jakubowski.18 Briefly, essentially fatty acid free human
serum albumin purchased from Sigma-Aldrich (St. Louis, MO) was dissolved in pH 7.4, 100
mM, sodium phosphate buffer containing 0.2 mM EDTA and incubated at 25 °C in the presence
of 4.6 mM HTL for 4 h at room temperature. The post-translational modification reaction was
quenched by filtering the protein reaction solution through a 10 kDa molecular weight cut-off
centrifugal membrane device (Millipore, Billerica, MA) to remove any unreacted HTL as well as
other low molecular weight byproducts such as Hcy. The protein retentate was rinsed twice with
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1 mL buffer aliquots to remove nonspecifically bound HTL or Hcy. The rinsed modified protein
was promptly reconstituted with buffer to obtain the N-Hcy-protein stock solution.
4.2.4 Sample Characterization
Electrospray ionization- time of fight-mass spectrometry (ESI-TOF-MS) was used to
verify the post-translational modification of HSA by HTL.

The mass spectrometry data

indicates that the in vitro modification reaction protocol used in this study is efficient and
typically yields a extensively modified HSA solution. The majority of the resultant HSA species
typically contained ~1 – 4 Hcy per protein molecule post-modification. A substantial signal
corresponding to dimeric HSA was also detected due to modification-induce oligomerization.
Based on these findings, the concentrations of the HSA and serum homocystamide solutions are
reported in units of mg/mL or μg/mL, assuming complete modification. Mass spectra (Figure
B.1) and additional discussion are provided in Appendix B.
Unless otherwise noted, N-Hcy-protein standard solutions were prepared by diluting the
stock solution with phosphate buffer. Excess biological materials were heat sterilized prior to
disposal in an approved biohazard waste container. All appropriate safety apparels such as
protective gloves, clothing, and eyewear were worn while handling the potentially biohazardous
human serum protein material.
4.2.5 Preparation of Sensor Solutions
N-Hcy-protein solutions were immediately treated with the GNP sensor in order to
minimize the loss of colorimetric response due to spontaneous intermolecular disulfide bonding
between modified proteins and other miscellaneous auto-oxidation processes.

The N-Hcy-

protein solutions used in this study were not treated with a disulfide reducing agent. Unless
otherwise indicated, a 100 μL aliquot of the N-Hcy-protein or control solution was treated with
200 μL of 1.0 mM GNP stock solution at room temperature. Changes in the visible absorption
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due to the GNPs and the nanoparticle-modified protein complex were monitored immediately at
520 nm and 620 nm, respectively. The UV absorption associated with the protein was monitored
between 220-280 nm. Protein-sensor solutions were typically diluted 2-fold prior to measuring
UV-visible absorption.
4.2.6 Instrumentation
Absorption measurements were acquired using a Shimadzu, model UV-3101PC UV-VisNIR, spectrophotometer with either quartz (UV-visible) or disposable polystyrene (visible only)
reduced volume cells. DLS measurements were performed using a Malvern Zetasizer Nano ZS
(Worcestershire, UK). TEM images were acquired with a JEOL model 100CX transmission
electron microscope using an acceleration voltage of 80kV. TEM specimens were prepared by
adsorbing a thin layer of the sensor-protein solution onto carbon-coated grids followed by airdrying. The sample grids were treated with 2% uranyl acetate staining reagent prior to TEM
imaging.
4.3 Results and Discussion
4.3.1 Nanoparticle-Serum Protein Compatibility Study
A preliminary assessment of the proposed GNP sensor was performed using the model
protein human serum albumin (HSA). HSA was chosen for these studies because it is a major
protein constituent in human serum, accounting for approximately half of the total serum protein.
In addition, it is known that highly stable albumin-GNP conjugates are readily obtained via
adsorption interactions under physiological pH and ionic strength conditions.19-21 However, it
was necessary to evaluate the behavior of the proposed HSA-GNP system under the conditions
used for these studies.
Figure 4.1 is an image of cuvettes containing equivalent concentrations of the GNP
sensor (~ 0.3 mM) in the presence of either HSA or HSA-homocystamide (0-85.2 mg/mL)
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dissolved in phosphate buffer (100 mM at pH 7.4). The protein concentration range used for this
study encompasses the expected physiological concentration range for HSA in human plasma,
~34 - 54 mg/mL.22 As expected, the GNPs were only sparingly soluble in the phosphate buffer
in the absence of HSA. The resultant metallic-grey colored suspension shown in Figure 4.1a is
slightly opaque due to scattering from salt-induced aggregation and precipitation of the GNPs.
This behavior is attributed to the citrate-capped GNPs becoming destabilized by the relatively
high ionic strength of the phosphate buffer.23

b)

c)

a)

0.0

9.2

27.5

45.8

64.2

85.2

[HSA], mg/mL
Figure 4.1 Photographs of the gold nanoparticle (GNP) sensor a) in the absence of protein b)
in the presence of unmodified HSA (9.2 - 85.2 mg/mL) and c) in the presence of HSAhomocystamide (9.2 - 85.2 mg/mL).
Cuvettes containing unmodified HSA (9.2 - 85.2 mg/mL) are shown in Figure 4.1b. All
samples were prepared in 100 mM phosphate, 0.2 mM EDTA buffer. Each cuvette contains 0.3
mM GNP. The nanoparticles remain stable and dispersed in the presence of unmodified HSA, as
indicated by the reddish-pink color of the sensor solutions. Notably, there is no discernable
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change in the color of the sensor solutions in response to increasing concentrations of
unmodified HSA, which suggests that nonspecific nanoparticle assembly does not occur in the
presence of unmodified HSA. Furthermore, the UV-vis absorption spectra shown in Figure 4.2a
are similar to those previously reported for bovine serum albumin-GNP conjugates dissolved in
10 mM phosphate at pH 7.0.19
The GNP sensor produced a significant colorimetric signal in response to increasing
concentrations of N-Hcy-protein, which is clearly visible in Figure 4.1c. The sensor solutions
transition from reddish-pink to a deep purple-violet color, which is easily distinguishable from
the highly scattering metallic grey-colored suspension produced in the absence of protein due to
salt-induced nanoparticle aggregation.
The corresponding UV-visible absorption spectra for sensor-protein solutions collected
approximately 20 min after treatment with the GNPs (Figures 4.1b-c) are provided in Figure 4.2.
The absorption spectra shown in Figure 4.2a indicate the absorption maximum (λmax) for the
GNP sensor in the presence of unmodified HSA is ~520 nm, which is comparable to absorption
of dispersed gold nanoparticles in water. No significant change in the visible absorption spectra
was observed in response to increasing concentrations of unmodified HSA over the
concentration range investigated in this study. Conversely, the absorption spectra of the sensor
in the presence of an equivalent concentration range of HSA-homocystamide have red-shifted
extended plasmon bands (Figure 4.2b). A proportional increase in UV absorption at the protein
absorption bands ~220 - 280 nm was also observed in response to increasing concentrations of
both unmodified HSA and HSA-homocystamide in the sensor solutions. A representative plot of
the colorimetric response of the GNP sensor detected at 620 nm in the presence of HSAhomocystamide is provided in Appendix B (Figure B.2). The colorimetric response was found to
be linear (r2 = 0.9849) over a range of HSA concentrations (2.8 - 28 mg/mL). The limit of
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detection (LOD) and calibration sensitivity for the method were 2.3 mg/mL and 2.7 AU ·
(µg/mL)-1, respectively. Collectively, these results suggest that the colorimetric signal produced
by the GNP sensor is due to HTL modification-directed nanoparticles assembly and not to saltinduced nanoparticle aggregation. Moreover, the stability of the GNP sensor in the HSAphosphate buffer solutions suggests that the GNP sensor will be stable in the presence of human
sera (vide infra).
a)

b)

Figure 4.2 UV-visible absorption spectra of GNP sensor solutions shown in Figure 1. a)
Unmodified HSA and b) N-Hcy-HSA. Extended plasmon bands are only observed for sensor
solutions containing HSA-homocystamide. The arrows indicate the change in absorption with
increasing HSA or HSA-homocystamide.
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4.3.2 Effect of Temperature on Sensing
Many GNP sensors reported in the literature are designed such that nanoparticle assembly
is achieved via reversible noncovalent interactions.24-26 Consequently, nanoparticle assembly is
often loosely associated and environment-dependent. For example, Mirkin et al. demonstrated
temperature-dependent reversible nanoparticle assembly over a decade ago using DNAfunctionalized GNPs.27 This system exploits noncovalent DNA hybridization interactions to
produce a colorimetric signal that could be effectively “switched on and off” by cycling the
solution temperature between 0 and 80 °C, the latter of which is well above the dissociation
temperature of the DNA-nanoparticle complex. Additionally, a temperature and pH-sensitive
Hcy GNP sensor was recently developed by Lim et al.14 This GNP sensor utilizes reversible
zwitterionic-type interactions to generate a colorimetric response.
A distinguishing characteristic of the proposed GNP sensor for N-Hcy-protein is that it
was designed to exhibit essentially irreversible binding behavior via thiol binding interactions.
In principle, a tightly bound nanoparticle-protein assembly would allow for highly stable and
long-lived colorimetric detection. Consequently, it was found that sensor solutions containing
HSA-homocystamide incubated in an 80 °C water bath for 20 min exhibited remarkable stability
as indicated by a persistent colorimetric signal. Only a very slight increase in colorimetric signal
was observed after exposing the sensor solutions to 80 °C for ~10 min. This result is likely
caused by additional GNP binding sites being exposed due to thermal denaturation of the
modified protein.
4.3.3 Confirmation of Nanoparticle Assembly
Transmission electron microscopy (TEM) was used to image the GNP sensor in the
presence of HSA and HSA homocystamide. As expected, the purple-colored GNP sensor- NHcy-protein solutions contained oligomeric HSA, which appears as a dark sponge-like film in
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the TEM image (33,000 × magnification) shown in Figure 4.3a. The GNPs appear as clearly
defined black dots in the TEM images. Further examination of Figure 4.3a reveals an assortment
of nanoparticle clusters within the oligomeric protein network. The multiplicity of shapes and
sizes of the nanoparticle assemblies in the sensor specimen is consistent with the broad extended
plasmon bands observed at 620 nm (Figure 4.2b).28,

29

The inset of Figure 4.3a (100,000 ×

magnification) shows an example of modification-directed nanoparticle assembly, a 4nanoparticle cluster within the oligomeric protein network. Other regions within the oligomeric
protein network containing GNP clusters are highlighted in Figure B.3 in Appendix B. These
data suggest that both modification-induced protein oligomerization and modification-directed
nanoparticle assembly occur concomitantly in the GNP sensor solutions containing N-Hcyprotein.
In contrast, neither nanoparticle assembly nor protein oligomerization is observed in a
specimen prepared from the red-colored GNP sensor solution containing unmodified HSA
(Figure 4.3b).

The unmodified protein appears as dark semitransparent spots in the TEM

images. Closer examination of the sensor specimens containing unmodified HSA reveals that
the spherical GNPs are randomly dispersed throughout the specimen, within individual protein
spots. The inset of Figure 4.3b shows GNPs in the presence of unmodified HSA at 100,000 ×
magnification. Nanoparticle assembly is not induced by unmodified HSA, presumably due to
the lack of N-Hcy-protein binding sites. The absence of significant nanoparticle assembly in the
unmodified protein sample is consistent with the absorption spectra shown in Figure 4.2a and is
consistent with the expected results for this detection scheme.
4.3.4 Proposed Clinical Detection Scheme
Biochemical sensor design requires careful consideration of the intended sample matrix.
Blood and urine samples have been traditionally collected from patients for use in generic
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a)

b)

Figure 4.3 Transmission electron micrograph images of the GNP sensor a) in the presence of
HSA-homocystamide at 33,000 × magnification (inset shows 100,000 × magnification of a 4nanoparticle cluster assembly within the oligomeric protein network), and b) in the presence of
unmodified HSA (inset shows 100,000 × magnification of unassembled GNPs surrounded by
unmodified HSA). The arrows indicate the location of the insets in lower magnification images.
clinical diagnostics. Urine analysis is a versatile medical screening procedure that has used
historically for the in vitro detection of a number of physiologically relevant analytes including
illicit drugs, steroids, and numerous other analytes. The detection of HTL in urinary excretions
71

has been reported.30 However, the existence of substantial amounts of N-Hcy-protein in urinary
excretions is not expected because of the relatively low protein content of urine. In contrast,
human serum is a more ideal sample medium for the protein sensor because it is relatively
protein-rich and thus more likely to contain detectable levels of N-Hcy-protein.

Another

potential advantage of working with human serum is that it is already routinely screened for
other cardiovascular disease risk factors such as cholesterol.
Unlike the purified HSA used in the previous studies, human serum is a complex medium
that consists of an assortment of proteins and small molecules, including carbohydrates, drugs,
hormones, etc, which may exist as free or protein-bound species. Human serum also contains
various thiol-containing species that could interfere with the GNP sensor. For example, cysteine
(Cys)29, glutathione29, and Hcy14 are typically found at micromolar concentrations in human sera.
Fortunately, these low molecular weight species can be easily removed from sera by use of a
molecular cutoff filter device prior to treatment with the GNP sensor.
Frozen whole human sera collected and pooled from healthy adult donors were purchased
from Sigma-Aldrich (St. Louis, MO) for use in this component of our study. The sera solutions
were faintly yellow in color and slightly turbid due to sparingly soluble components. The protein
content of the sera was determined by a gravimetric assay of lyophilized 1 mL aliquots after
washing with deionized water. The average protein concentration of the aliquots was 52.4 ± 6.7
mg/mL (n = 4). Sera were typically diluted with phosphate buffer to obtain ~65 % (v/v) serum
solution in order to decrease the viscosity and turbidity.

The diluted serum was post-

translationally modified with HTL in vitro as previously described. Scheme 4.2 depicts the
proposed scheme for detecting serum N-Hcy-protein using the GNP sensor. First, the protein
modification mixture is purified by use of centrifugal 10 kDa MWCO filters. Next, the modified
N-Hcy-protein retained by the MWCO filter is promptly reconstituted with phosphate buffer in
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order to obtain a stock solution. The resultant N-Hcy-protein is then immediately treated with
the GNP sensor. Finally, the resultant GNP- N-Hcy-protein solution is diluted and transferred to
a cuvette for monitoring of the colorimetric response.

Scheme 4.2 Proposed method for the detection of N-Hcy-protein in human sera.
Representative absorption plots of the sensor under various experimental conditions are
shown in Figure 4.4. Similar to the HSA model studies, unmodified sera were found to be
reasonably stable and did not produce appreciable shifts in the plasmon resonance band over the
sera concentration range investigated in this study (Figure 4.4a). Consistent with the HSA model
studies, the sensor also produces extended plasmon resonance bands in the presence of serum NHcy-protein (Figure 4.4b). Figure 4.4c is a comparison plot of sensor signal versus serum
protein concentration. It is apparent that the colorimetric signal detected at 620 nm increases in
response to increasing concentrations of serum N-Hcy-protein, but remains relatively constant in
the presence of equivalent concentrations of unmodified sera. Notably, the sensor response
deviates from linearity at modified serum concentrations lower than ~5 mg/mL, giving a
background signal of ~0.12 AU This effect is partially attributed to the GNPs being sparingly
soluble in the phosphate buffer at low protein concentrations, which produces increased sample
73

turbidity and light scattering. The colorimetric response in the range of 6.0 - 14 mg/mL modified
serum protein provides excellent linearity (r2 = 0.9994) and a calibration sensitivity of 13.6 AU ·
(µg/mL)-1. The calculated LOD of the serum method is 5.2 mg/mL.
Human plasma can contain from 0.1 – 13 µM N-Hcy-protein, which is comparable to the
mg/mL protein concentration range.31

Accordingly, a solution containing 2.3 mg/mL sera

homocystamide and 0.7 mM GNP was allowed to react as previously described. The resultant
solution containing the HSA-homocystamide-GNP complex was serially diluted with ultra pure
water in order to evaluate the dilutional stability of the N-Hcy-protein-GNP assembly at
concentrations well below the physiologically relevant range. The resultant curve exhibited
excellent linearity (r2 = 0.9899), which is expected for a tightly bound colorimetric complex
(Figure B4 in the Appendix B). The sensor also provided an exceptional calibration sensitivity,
0.30 AU · (ng/mL)-1.

These data further support the hypothesis of modification-directed

nanoparticle assembly via chemisorption and intermolecular disulfide bonding interactions.
Overall, the proposed GNP sensor exhibited exceptional performance for the detection of the in
vitro modified serum protein species used in these studies. This is largely because freshly
prepared N-Hcy-protein was promptly treated with the sensor, thereby minimizing the effects of
auto-oxidation in the protein reaction mixture. However, essentially all of the N-Hcy-protein
produced in vivo exist in an oxidized state and would thus be unavailable for binding with the
sensor. Therefore, the issue of disulfide bound N-Hcy-protein species must be addressed prior to
applying this method to screening clinical samples.
4.4 Conclusions
We have demonstrated a straightforward colorimetric method for the detection of serum
N-Hcy-protein, an emergent cardiovascular disease biomarker. GNP assembly was observed

74

a)

c)

b)

Figure 4.4 Visible absorption spectra of the GNP sensor in response to human sera. a) in the
presence of unmodified human sera and b) in the presence of human serum homocystamide. c)
Sensor response at 620 nm in the presence of modified (○) and unmodified (■) sera versus
human serum concentration, (2 – 14 mg/mL). The arrow indicates the change in signal at 620
nm with increasing concentrations of human serum homocystamide.
only in the presence of serum N-Hcy-protein. TEM images of the GNP sensor in the presence of
unmodified and HTL-modified serum protein are consistent with the absorption data. The TEM
images are also indicate modification-directed nanoparticle assembly as well as modificationinduced protein oligomerization. The nanoparticle- N-Hcy-protein complex exhibited excellent
stability and irreversible binding behavior under the condition used in this study. Studies are
underway to adapt this model GNP biochemical sensor for use in clinical sera samples. Based
on our studies to date, we believe that the approach reported here will lead to the development of
a GNP sensing scheme that could aid in the rapid detection and diagnosis of cardiovascular
disease.
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CHAPTER 5
SPECTROCHEMICAL STUDIES OF N-HOMOCYSTEINYLATED GOLD
NANOBIOCONJUGATES
5.1 Introduction
The biomedical significance of homocysteine (Hcy) as a cardiovascular disease (CVD)
biomarker has only recently emerged.1, 2 The relationship between Hcy and CVD was further
strengthened by clinical data that suggest lowering blood Hcy levels reduces risk of acute
myocardial infarction.3 The most commonly used techniques for Hcy analysis are HPLC, CE,
and IA methods.4 Functionalized chromophores and fluorophores have also been used to achieve
more rapid and direct detection.5-8 These conventional methods measure total blood Hcy (Hcyt),
but are often incapable of discriminating the N-Hcy-protein fraction. N-Hcy-protein is the
product of a unique type of post-translational protein modification that involves site specific
acylation of proteins at ε-NH2 groups on lysine residues by homocysteine thiolactone (HTL), the
highly reactive thioester metabolite of Hcy.9 Like Hcy, elevated plasma levels of N-Hcy-protein
correlate with increased risk of CVD.10
Plasmon resonant gold nanosensors provide a versatile platform for biomedical
analyses.11 GNPs have proven to be especially well-suited for the detection of aminothiol
biomarkers such as Hcy, Cys, and glutathione.12-14 The first plasmon resonance detection scheme
for N-Hcy-protein was described in Chapter 4. It was found that GNPs undergo irreversible selfassembly in the presence of N-Hcy-protein to yield a rapid and direct colorimetric response. The
resultant nanoparticle assemblies exhibited excellent thermal and dilutional stability. These
interesting findings warranted further examination of the underlying physiochemical processes.
Nanobioconjugates are commonly used to probe complex biomolecular and physiochemical
78

phenomenon such as protein binding15 and protein conformational change.16, 17

In this study,

gold nanobioconjugates were subjected to in situ N-homocysteinylation and evaluated on the
basis of plasmon resonance absorption, bioconjugate assembly growth, and susceptibility to
thermally-induced protein conformational change.
5.2 Methods
5.2.1 Materials
L-homocysteine thiolactone hydrogen chloride, hydrogen tetrachloroaurate trihydrate,

trisodium citrate, ethylenediamine tetra-acetic acid (EDTA), tris(2-carboxyethyl)phosphine
(TCEP) hydrochloride and all other reagents used for the preparation of buffer and serum protein
solutions were obtained from Sigma-Aldrich (St. Louis, MO) at the highest purity available and
used as received. Ultra-pure water (18.2 MΩ) was obtained from an Elga model PURELAB
Ultra water filtration system.
5.2.2 Synthesis of Nanobioconjugates
Citrate-capped GNPs (ca.13 nm) were synthesized using the Turkevich-Frens method.18,
19

Hydrogen tetrachloroaurate trihydrate was dissolved in water and heated to reflux while

stirring, followed immediately by the addition of a 40 M excess of trisodium citrate-water
solution, which facilitates reduction of the gold salt. The reaction mixture was allowed to reflux
for approximately 25 min until completion of the redox reaction and formation of GNPs, which
was indicated by a change in solution color from pale yellow to dark-red. Excess citrate was not
removed from solution in order to minimize nonspecific GNP aggregation during long term
storage.19 The concentration of the GNP solution was 1.0 mM, assuming complete reduction of
the gold salt. The GNP solutions was purified using a 0.45 μm poly(tetrafluoroethene) syringe
filter device and stored at room temperature in an amber glass bottle for no more than one month.
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Nanoparticle size was confirmed with transmission electron microscopy (TEM). Protein-GNP
bioconjugates (nanobioconjugates) were prepared by combining 4 mL of the GNP stock solution
and 2 mL of 80 mg/mL cytochrome c (cyt c) or human serum albumin (HSA) dissolved in pH
7.4 phosphate buffer. The GNP-protein mixture was incubated at 37 ºC for at least 12 h to allow
for maximum protein adsorption and surface coverage. Unbound protein and excess buffer were
removed from the nanobioconjugates using a Amicon Ultra 100 kDa molecular weight cut-off
centrifugal (MWCO) filter devices (Millipore, Billerica, MA).

The resultant solution was

concentrated to 0.5 mL in the MWCO filter and subjected to 5 successive 1 mL washes with
phosphate buffer. Lastly, the nanobioconjugates were reconstituted to the original volume with
phosphate buffer and stored at 4 ºC.

Human serum nanobioconjugates were prepared as

described above except 4 mL of the GNP stock solution was directely added to 2 mL of human
serum (80 mg/mL protein) purchased from Sigma-Aldrich, St. Louis, MO.
5.2.3 N-homocysteinylation of Nanobioconjugates
Post-translational N-homocysteinylation of nanobioconjugates was accomplished by
incubation with HTL in 100 mM, sodium phosphate buffer containing 0.2 mM EDTA at room
temperature for 3 h.

Excess Hcy and unreacted HTL were removed from the modified

nanobioconjugates by 4 successive 1 mL buffer washes in a 10 kDa MWCO filter. Purified
nanobioconjugate solutions were reconstituted to the original volume with the desired buffer.
5.2.4 Instrumentation
UV-Vis absorption spectra were acquired using a Shimadzu UV-3101PC UV-Vis-NIR
equipped with thermoelectric temperature control.

Dynamic light scattering (DLS)

measurements were made with a Malvern Zetasizer Nano ZS dynamic light scattering
spectrometer (Worcestershire, UK) equipped with thermoelectric temperature control.
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Nanobioconjugates and reagents were purified using a 0.1 µm syringe filter device prior to DLS
analysis. The assembly behavior of nanobioconjugates (8.7 × 10-2 mM) was monitored with
DLS immediately after the additions of HTL (3.3 × 10-3 mM). Each DLS data point is the
composite of eleven consecutive 10 sec measurements. Circular dichroism (CD) spectroscopy
measurements were made using an Aviv Model 62DS spectrometer equipped with a 1 mm path
length quartz cell and temperature controlled cell holder. CD spectra were acquired in triplicate
between 200 and 250 nm. CD response is reported as ellipticity and displayed in units of
millidegree (θ). Protein standards and nanobioconjugate solutions were typically diluted to ~0.1
mg/mL protein in pH 7.4, 10 mM phosphate buffer to obtain optimum CD signal. TEM imaging
was performed using a JEOL model 100CX transmission electron microscope at 80 kV applied
acceleration voltage.

TEM specimens were prepared by depositing a thin layer of the

nanobioconjugate solution onto carbon-coated copper grids followed by air-drying. SDS-PAGE
separations were performed with a Mini-Protean 3 gel electrophoresis unit equipped with a 1000
V power supply (Bio-Rad Laboratories, Hercules, CA). Standard precast 4-20% Tris HCl
polyacrylamide mini-gels were also purchased form Bio-Rad. When necessary, TCEP (50 mM)
was added to the sample buffer prior to separation to achieve disulfide reduction.

Gel

separations were visualized by staining with coomassie blue for ~5 h, followed by destaining
with water for at least 5 h. Gel images were acquired using a Kodak Gel Logic 200 analyzer
purchased from Eastman Kodak Co. (Rochester, NY).
5.3 Results and Discussion
5.3.1 Characterization of Nanobioconjugates
We have previously shown that GNPs behave as a concentration-dependent colorimetric
sensor for N-homocysteinylated serum protein.20 The resulting colorimetric signal was found to
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be long-lived and thermally stable. It is suspected that modification-directed GNP assembly and
the subsequent colorimetric response are mediated by various protein and thiol binding
interactions at the nanoparticle surface interface. Nanobioconjugates are an ideal molecular
probe for biochemical processes. The protein component behaves as is an immobilized
biomolecular ligand, while the GNP component serves as plasmon resonant biochemical
indicator. The use of GNPs as biochemical and biomedical sensors has been reviewed the
literature.11 The principle for plasmon resonant GNP sensing is that dispersed nanocolloids
having dimensions on the order of 10 nm typically exhibit intense localized surface plasmon
resonance in the visible spectrum at ~520 nm, resulting in a red color solution. However,
biochemically induced GNP self-assembly yields extended plasmon bands at ~620 nm, which
causes a characteristic red-to-blue color change.21
Since human serum or plasma are usually the preferred biological media for clinical
screening applications,10, 22 albumin and human serum nanobioconjugates were studied initially.
Representative visible absorption spectra of solutions containing nanobioconjugates prepared
from HSA (HGNPs) and serum (SGNPs) are shown in Figure 5.1. Dispersed serum proteinGNP bioconjugates have an SPR absorption maximum centered at ~526 nm, which is slightly
red-shifted from the absorption maximum of dispersed unconjugated GNPs (523 nm). This shift
in SPR absorption maximum is generally indicative of successful bioconjugation.16,

23

N-

homocysteinylation of the nanobioconjugates was achieved by treatment with 2.5 mM HTL.
Modification of the HGNP and SGNP nanobioconjugates resulted in the appearance of
characteristic extended plasmon bands (EPBs) at ≥620 nm and a change in solution color from
red to blue-violet. The spectral profiles of HGNPs and SGNPs are similar because albumin is
the principal protein component in both systems. However, the relative change in colorimetric
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signal detected at 620 nm for modified SGNPs was ~1.5-fold greater than what was observed for
modified HGNPs.

Based on these data, SGNPs appear to be more reactive toward N-

homocysteinylation than HGNPs. One possible explanation is that serum contains additional
protein constituents that are more reactive towards modification than albumin such as transferrin,
α2-macroglobulin, and low density lipoprotein.24

a)

b)

Figure 5.1 Visible absorption spectra for unmodified (solid line) and 2.5 mM HTL-modified
(dashed line), a) HGNP and b) SGNP nanobioconjugates.
Cyt c-GNP (CGNP) nanobioconjugates were also included in this study because cyt c
provides an excellent model protein for studying N-homocysteinylation.
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For example, we

previously demonstrated that cyt c is highly susceptible to N-homocysteinylation and
modification-induced protein oligomerization via disulfide cross-linking under physiological pH
conditions.25 This is because cyt c (12 kDa) is rich in lysine residues (~20% w/w),26 the target
site for post-translational protein modification by HTL.
The effect of N-homocysteinylation on CGNP nanobioconjugates is illustrated in Figure
5.2. Unmodified CGNPs remained dispersed and appeared red ( λmax ~ 528 nm) in solution. In
contrast, N-homocysteinylation caused a simultaneous decrease in SPR absorption at 528 nm and
the emergence of broad extended plasmon bands appeared between 620-750 nm. Consequently,
the color of the CGNP solution transitioned from red to dark blue-violet, thereby indicating the
formation of relatively large nanobioconjugate assemblies. The dark blue-violet color typically
persisted for ~1 h and gradually diminished due to precipitation of assembled nanobioconjugates.
Complete precipitation occurred in 72 h, resulting in a near-colorless solution.

Figure 5.2 Visible absorption spectra of CGNP bioconjugates (0.3 mM) modified with
increasing concentrations of HTL (0-2.5 mM).
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5.3.2 Monitoring Modification-Directed Nanobioconjugate Assembly
Since

the

colorimetric

response

produced

by

the

N-homocysteinylated

nanobioconjugates is due to self-assembly, dynamic light scattering (DLS) spectroscopy was
utilized to assess modification-directed GNP assembly. According to DLS measurements, the
hydrodynamic

diameter

(Dh)

values

for

unmodified

HGNP,

SGNP,

and

CGNP

nanobioconjugates were approximately 45, 91, and 22 nm, respectively, at 25 ºC. As one would
expect, the nanobioconjugates were significantly larger than unconjugated GNPs (~17 nm,
measured by DLS) due to the adsorbed protein layer. The trend in Dh values for the proteinpassivated GNPs was found to be generally consistent with the size of the proteins adsorbed on
the surface of the GNPs.
Time-course DLS data acquired for HGNPs and SGNPs is shown in Figure 5.3. This
study was conducted at 80 ºC in order to allow the process to be satisfactorily monitored in a 30
min time period.

The growth profiles for HGNP (Figure 5.3a) and SGNP (Figure 5.3b)

bioconjugate assemblies were very similar. For instance, the profiles of both nanobioconjugate
systems exhibit an initial sharp decrease in the Dh prior to the commencement of assembly
growth. This feature is likely the result of temperature-induced desorption of loosely associated
protein on the surface of the GNPs. Another explanation is that weak interparticle associations
may be disrupted at 80 ºC, thereby decreasing the mean Dh of bioconjugates.

The size of these

HGNP and SGNP bioconjugate assemblies grew to 70 and 135 nm, respectively. Dh values for
unmodified HGNPs and SGNPs stabilized at ~33 and 72 nm, respectively. Conversely, CGNPs
are much more responsive to modification by HTL. A 10-fold increase in nanobioconjugate
assembly size was observed within the first 10 min of monitoring at 25 ºC (Figure 5.3c).
Nanobioconjugate assembly growth approached 300 nm and eventually produced insoluble
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micron-sized superstructures, which began to precipitate from the blue-colored solution after
~1h. No appreciable nanoparticle assembly or change in solution color was detected in control
solution containing unmodified CGNPs (Figure 5.3c).

Corresponding time course visible

absorption data are provided in Appendix C.
b)

a)

c)

Figure 5.3 Time course dynamic light scattering (DLS) plots illustrating nanostructure growth
for unmodified (●) and N-homocysteinylated (○) nanobioconjugates, a) HGNPs b) SGNPs, and
c) CGNPs.
Visualization of nanostructures resulting from modification-directed bioconjugate
assembly was achieved by use of TEM (Figure 5.4). Modification of HGNP (Figure 5.4a) and
SGNP (Figure 5.4b) nanobioconjugates yielded relatively small structures that resemble the
GNP clusters observed in previous studies.20 Modified CGNPs stimulated prolific nanoparticle
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assembly, which formed micron-sized superstructures (Figure 5.4c). Note that regions consisting
of multiple layers of CGNPs appear darker in the TEM image. Unmodified nanobioconjugates
remained well-dispersed (Figure C1 in Appendix C). Collectively, these data suggest that the
degree of nanobioconjugate assembly is protein-dependent.
5.3.3 Assessing Modification-Induced Protein Conformational Change
The pathological effects of post-translational protein N-homocysteinylation are believed
to have implications for vascular tissues and CVD. In particular, modification of protein by HTL
is known to cause denaturation and loss of biological activity, which could induce vascular tissue
damage and atherogenesis.27-30 Jakubowski et al. recently used CD spectroscopy to study the
effect of HTL-modification on cyt c protein structure.31 Findings from this study indicate that
modification did not significantly change the conformation of cyt c. To date, CD studies of Nhomocysteinylation-induced conformational changes in nanobioconjugats have not been
reported.
In this study, CD measurements were acquired for respective nanobioconjugate systems
under identical protein and buffer concentration conditions in order to allow direct spectral
comparison. The CD spectra shown in Figure 5.5 exhibit the typical ellipticity minima at ~208
and 222 nm, which are indicative of the α-helical structural component of protein. In all cases, a
small upward shift in CD spectral profile was observed post-modification, possibly indicating
protein denaturation due to a loss of α-helical structure.32 Figures 5.5a and b illustrate the
temperature-dependence of ellipticity resulting from unmodified and modified HGNPs,
respectively. The difference in ellipticity for unmodified and modified HGNPs was significantly
enhanced by heating the solutions for 10 min at 80 ºC. Although SGNP bioconjugates exhibited
less defined spectral minima (Figures 5.5c and d), the spectral behavior of SGNP
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nanobioconjugate system before and after heating was essentially identical to the HGNP system.
Modification of unmodified and modified CGNPs at 25 ºC resulted in a much greater change in
ellipticity but heating at 80 ºC did not yield additional enhancements (Figures 5.5 e and f).

a)

b)

c)

Figure 5.4 TEM images of N-homocysteinylated a) HGNP, b) SGNP, and CGNP
nanobioconjugates.
The observed thermal stability of CGNP bioconjugates is consistent with previously
reported observations.33

Based on these data, one might conclude that N-homocysteinylation of

the bioconjugates does not induced gross protein denaturation at room temperature. However,
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differences in ellipticity for modified HGNP and SGNP nanobioconjugates were more evident
after heating, which may be indicative of protein denaturation and decreased colloidal stability in
modified systems.
a)

b)

c)

d)

f)

e)

Figure 5.5 CD spectra of unmodified (solid line) and modified (dashed line) nanobioconjugates
a) HGNPs at 25 ºC, b) HGNPs after 10 min incubation at 80 ºC, c) SGNPs at 25 ºC, d) SGNPs
after 10 min incubation at 80 ºC, e) CGNPs at 25 ºC and f) CGNPs after 10 min incubation at
80ºC.
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5.3.4 Modification-Induced Changes in Redox Potential of Cyt c Nanobioconjugates
The use of cyt c as a spectrochemical redox indicator is well established in the literature. 23,
33, 34

Briefly, the heme moiety in cyt c can exist in an oxidized state (Fe3+), which is usually

indicated by prominent Soret and Q-band peaks at ~408 and 530 nm, respectively. Reduction of
the heme is indicated by a shift in the Soret band from 408 to ~416 and the appearance of new Qbands at 520 and 550 nm.
CGNP nanobioconjugates were further studied with visible absorption spectroscopy in
order to assess modification-induced changes in the redox potential. Initial attempts to observe
the visible absorption of cyt c in the purified CGNP solutions were unsuccessful due to spectral
overlap with SPR band of GNPs. For this reason, nanobioconjugate solutions were prepared in
pH 7.4 phosphate buffer and spiked with additional cyt c 0.1 mg/mL in order to allow
observation of spectral redox features. Representative absorption spectra from this study are
shown in Figure 5.6. The unmodified mixture yielded peaks at 410 and 533 nm corresponding to
the cyt c Soret and SPR absorption bands, respectively (dotted line).

N-homocystenylation of

the mixture resulted in the appearance of Q-bands at ~520 and 550 nm as well as extended SPR
bands at ≥ 620 nm (solid line). This result indicates simultaneous reduction of cyt c and
modification-directed nanobioconjugate assembly. Cyt c reduction was also further signified by
a characteristic shift in the Soret band. The gradual disappearance of the extended SPR bands
after 24 hr is indicative of precipitation of large-sized nanobiocojugate assemblies (dashed line).
The remaining absorption peaks are due to reduced unconjugated cyt c. Given that the redox
potential for denatured cyt c is less than that of the native protein,35 the observed redox behavior
is also consistent with modification-induced protein denaturation.

Therefore, we infer that

denaturation allows the heme group of cyt c to be exposed to solvent, where it undergoes redox.
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Figure 5.6 UV-vis spectra of CGNP nanobioconjugate solution spiked with 0.1 mg/mL cyt c
unmodified before (dotted line), immediately after N-homocysteinylation with 2.5 mM HTL
(solid line), and 24 hr after modification (dashed line).
5.3.5 Effects of Disulfide Reduction on Nanobioconjugate Association
Interparticle association among N-homocysteinylated nanobioconjugates is presumed to
be the result of disulfide cross-linking. This hypothesis was tested by treating modificationderived nanobioconjugate assemblies with tris [2-carboxyethyl] phosphine (TCEP), a non-thiol
containing disulfide reducing agent known to be thiol-probe compatible.36 In this study, gel
electrophoresis was used to evaluate nanobioconjugate associated based on the principle of size
exclusion. SDS-PAGE separations of assembled nanobioconjugates performed on 4 - 20 %
gradient polyacrylamide gels are shown in Figure 5.7. The rectangles in the image approximate
the location of the stacking region of the gel, which contains pores large enough to accommodate
assembled nanobioconjugates.

The remainder of the gel, the resolving region, contains

progressively smaller pores that are not large enough to accommodate assembled
nanobioconjugates. Assembled HGNPs resulting modification with 10 and 20 mM HTL are
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mostly retained in the stacking region of lanes a and b, respectively. Notably, more material is
retained in the stacking region of lane b than lane a; because the degree of nanobioconjugate
assembly is proportional to HTL concentration. Corresponding HGNP experiments conducted
under reducing conditions, 50 mM TCEP, resulted in dissociation of assembled
nanobioconjugates as was indicated by a significant decrease in the amount of material in the
stacking region of lanes c and d. Consequently, more material permeated into the smaller pores
of the resolving region of the gel. This outcome was mirrored in experiments performed with
SGNP nanobioconjugates (lanes e-h). Neither unmodified nor modified CGNPs migrated into
the gel matrix under normal or reversed polarity condition, presumably due to lack of sufficient
binding between SDS and the CGNP nanobioconjugates. Nevertheless, these finding suggest
that modification-derived nanobioconjugate assemblies are covalently stabilized by interparticle
disulfide cross-linking.
a

b

c

e

d

f

g

h

Figure 5.7 SDS-PAGE separations of serum nanobioconjugate assemblies resulting from
modification with 10 and 20 mM HTL) before (lanes a and b, respectively) and after treatment
with TCEP (lanes c and d, respectively). Identical separations performed with SGNP
bioconjugate assemblies are shown in lanes e-h. The stacking regions of the gels are indicated
by rectangles.
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5.4 Conclusions
In summary, we have reported a spectroscopic investigation of the physiochemical
mechanisms of N-homocysteinylation-directed GNP assembly.

Nanobioconjugates prepared

from HSA, serum, and cyt c were examined in this study. UV-vis spectroscopy studies suggest
that the red-to-blue color change observed post-modification is the result of nanobioconjugate
assembly, which is indicated by the appearance of extended SPR bands at ≥620 nm. It was also
found that modification of HGNPs and SGNPs yielded moderate colorimetric responses.
Conversely, CGNPs were much more responsive to modification and produced extended SPR
bands with greater intensity and more dramatic color changes. Time course DLS studies were
conducted to characterize unmodified GNP bioconjugates and to monitor modification-directed
bioconjugate assembly. Modified HGNPs and SGNPs exhibited similar assembly behavior,
which resulted in moderate assembly growth, over a 30 min period at 80 ºC. In contrast,
modified CGNPs yielded a 10-fold increase in assembly size after 30 min at 25 ºC. CD and
visible spectroscopy data for nanobioconjugates indicate protein conformational change, which
could signify modification-induced protein denaturation.

In general, N-homocysteinylated

nanobioconjugates were found to be less resistant to heat-induced protein conformational
change. In addition, modification-induced nanobioconjugate association was shown to be the
result of interparticle disulfide cross-linking.
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CHAPTER 6
IMMUNOAFFINY EXACTION OF POLYCYCLIC AROMATIC HYDROCARBONS
FROM ATHEROSCLEROTIC HEART TISSUES
6.1 Introduction
Although there is currently no formal link between CVD and PAHs, exposure to tobacco
smoke is both a CVD and a potential source for PAH exposure risk factor.1 In fact, tobacco
smoking releases over 4000 toxic chemical substances into the environment, including PAHs.2
Table 6.1 lists of some of the PAH compounds found in cigarette smoke. Since PAHs are
ubiquitous in the environment, it is highly likely that some degree of bioaccumulation occurs in
cardiovascular tissues. Various anthropogenic chemicals have been detected in heart plaque, but
PAHs were not specifically identified.3

Although PAHs are routinely analyzed with gas

chromatography-mass spectrometry (GC-MS), atherosclerotic plaques and tissue presents a
challenge due to the lack of selective extraction techniques for solid samples. For this reason,
updated methodologies are needed to address this problem. We have proposed the use of a novel
immunoaffinity-based method.
Table 6.1 PAHs present in cigarette smoke.2

Anthracene

Chrysene

Indole

Benz[a]anthracene

Dibenz[a,h]anthracene

Methylamineethylchrysene

Benzo[a]pyrene

Dibenzo[a,l]pyrene

Naphthalene

Benzo[b]fluoranthene

Fluoranthene

Phenanthrene

Organic liquid-solid (OLS) extraction is commonly used in the analysis of lipidcontaining materials such as atherosclerotic plaques and tissues.

While OLS extraction is

capable of removing PAHs from solid fatty samples, it is poorly selective. In this work, OLS
extraction and immunoaffinity extraction (IAE) are used in tandem to selectively isolate PAHs
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from human atherosclerotic tissue samples harvested from the cadavers of two elderly male
subjects. The tissue extracts were subsequently analyzed by use of GC-MS.
6.2 Methods
6.2.1 Materials
Atherosclerotic plaque samples were provided by Dr. R. E. Tracy of the Louisiana State
University Medical School, New Orleans, LA.

Neat anthracene, fluorene, naphthalene,

phenanthrene, and pyrene were obtained at > 99% purity from AccuStandard, Inc. (New Haven,
CT).

UltraLink fritted 5 mL low-performance chromatography columns and azlatone-

functionalized polyacrylamine beads, were obtained from Pierce Biotechnology, Inc. (Rockford,
IL). Maxi-clean C18 solid phase extraction cartridges with 600 mg bed volume were obtained
from Alltech Associates Inc. Monoclonal anti-PAH antibodies (clone 2Z11) raised against
phenanthrene were obtained from Strategic Biosolutions, Inc. (Newark, DE). Buffer salts and all
other reagents used in this work were purchased from Sigma-Aldrich Chemical Co. (St. Louis,
MO) in the highest available purity.
6.2.2 Preparation of Atherosclerotic Tissue Samples
Human tissue samples were handled according to standard laboratory biohazard protocol.
Protective eyewear, gloves, and a lab coat were worn at all times. Sample preparation steps
involving biohazard materials were performed inside a disposable biohazard glove box purged
with nitrogen. Atherosclerotic plaque-tissue samples were removed from aortas immediately
upon arrival and stored in a cryogenic freezer at -77°C. Plaque samples were thawed to room
temperature then carefully weighed prior to being homogenized in hexane. The organic solvent
and sample mixtures were subsequently sonicated at 50°C for 4 hr. The organic layer was
removed from each sample and stored in an amber glass vial. The aqueous layer was discarded
after sterilization with a 10% sodium hypochlorite solution for 1 hr. Organic extracts with
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significant adipose content were placed in an ice bath to precipitate the lipids, and carefully
decanted from the lipid precipitate. The lipid precipitate was discarded after sterilization.
Extracts were then concentrated to near dryness using a gentle stream of activated carbon filtered
nitrogen. The samples were then reconstituted with 5 mL of HPLC grade 2-propanol. All
glassware and laboratory utensils used in sample preparation were thoroughly disinfected with a
10% sodium hypochlorite solution then heat sterilized at 100 ºC overnight. All solid and liquid
waste derived from plaque or tissue samples were discarded in biohazard waste containers.
6.2.3 Immunoaffinty Extraction Protocol
Phosphate buffered saline (PBS) was prepared by dissolving the appropriate amounts of
sodium phosphate and sodium chloride in ultra-pure water (18 MΩ) followed by pH adjustment
to 7.4 using either strong acid or base. Citrate-carbonate coupling buffer for the antibody
immobilization reaction was prepared by dissolving the appropriate amounts of sodium
carbonate and trisodium citrate in doubly deionized water to obtain 0.1 M sodium carbonate and
0.6 M sodium citrate at pH 9.0. Wash solutions for IAE column rinses were prepared by
dissolving sodium chloride in water to obtain a 1.0 M solution. The IAE column elution buffer
was prepared by dissolving sodium phosphate (monobasic and dibasic) in water followed by pH
adjustment to 7.4.
6.2.4 Column Frabrication
IAE columns used in this study were fabricated by covalently immobilizing anti-PAH
antibodies to the chromatographic support according to manufacturer protocol.

Breifly,

monoclonal antibodies were dissolved in pH 9.0 citrate-carbonate coupling buffer then added to
azlactone-activated polyacrylamide beads so that the antibody solution is 2-fold greater than the
swell volume for the dry beads. The slurry mixture was allowed to react at room temperature for
1hr while mixing. Antibody immobilization occurred via nucleophilic attack at the azlactone
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groups by the amino-terminus of the antibody, resulting in a covalent linkage.

The

immobilization reaction mixture was quenched for 3 hr with 3M ethanolamine. The resulting
slurry was used to pack a low-performance “gravity-flow” chromatography column. The column
was then filled with 20:80 (v/v) ethanol:phosphate buffer and stored at 4°C.
6.2.5 Extract Preparation
Prior to IAE, organic extracts were diluted with pH 7.4 PBS to obtain a solution with
no more than 5% organic solvent. The extract solutions were loaded onto the IAE column at 2
mL/min to allow for antibody binding. Next, weakly bound sample components were rinsed
away with 10 column volumes of the wash solution. The target analyte was then removed from
the column by rinsing with 5 column volumes of the elution buffer (ph 2.5 phosphate). The
eluent was immediately reconcentrated and solvent exchanged with dichloromethane using C18
solid phase extraction. The solvent exchange step is necessary because phosphate buffer is not
compatible with GC-MS.
6.2.6 Instrumentation
A Hewlett Packard 5971A gas chromatography-mass spectrometer (GC-MS) equipped
with a DB-5 reversed phase column and electron impact ionization (EI) were used for the
analysis of PAH extracts from atherosclerotic plaque samples. The temperature gradient was
ramped at 10°C/min, from 40°C to a holding temperature of 280°C, for a total run time of 40
min. Mass spectra were collected in total ion chromatogram (TIC) mode. Peak identifications
were further verified by visual comparison of EI fragment patterns with those in the Wiley7N.L
database. Since humans possess the ability to degrade PAHs via cytochrome P-450 (naphthalene1,2-dioxygenase) pathways,4, 5 an effort was made to identify both parent compounds and PAH
metabolites.
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6.3 Results and Discussion
6.3.1 Gas Chromatography-Mass Spectrometry Analysis of Polycyclic Aromatic
Hydrocarbons Standards
Figure 6.1 shows a representative GC-MS total ion chromatogram (TIC) for a PAH
standard mixture containing fluorene, phenanthrene, anthracene, and pyrene.

The peak

identification software was unable to distinguish the structural isomers phenanthrene and
anthracene, which have nearly identical EI fragmentation patterns. Thus, it was necessary to
consider the relative chromatographic retention times in order to obtain positive identification.
The total elapsed time for GC-MS analysis was less than 16 min.
a)

b)

Figure 6.1 Mass spectra (TICs) of a) mixture containing 10 ppm PAH standards: 1) fluorene,
2) phenanthrene, 3) anthracene, and 4) pyrene. b) mass spectra for phenanthrene and anthracene
with molecular ion 178 at 100% abundance.
6.3.2 Analysis of Atherosclerotic Tissues Extracts
The atherosclerotic tissue samples used in this study were harvested from two elderly
male subjects: 1) a 69 year old African American male, and 2) a 70 year old Caucasian male. No
addition information about the subjects was provided. Two specimens (A and B) were provided
for each sample. The sample masses recorded for 1A, 1B, 2A, and 2B were 12.14 g, 3.84 g, 5.73
g, and 2.41 g, respectively.

The mass of sample 1A was larger than the other samples,
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presumably due to high water content. It was noted that all samples contained a combination of
fatty plaque, endothelial tissue, and aqueous material.

Respective sample specimens were

combined homogenized and extracted using the OLS-IAE method.
Internal standards were not used in these preliminary studies. Background GC-MS
spectra were collected for column blanks and all organic solvents to confirm that baseline signal
was minimal. Figure 6.2 shows typical total ion chromatographs (TICs) for atherosclerotic
tissues extracted with hexane only versus the OLS-IAE and method, respectively.
a)

b)

Figure 6.2 Representative GC-MS TICs for atherosclerotic plaques extracted using: a) organic
extract only and b) the OLS-IAE method.
Table 6.1 provides the structures and retention times for the compounds detected in
sample 1 within a 5.83 min elution window. Interestingly, 2,4-Di-tert-butylphenol (11.38 min)
and [1S-(1a,3ab,4a,8ab)]-decahydro-4,8,8′-trimethyl-9-methylene-1,4-methanoazulene (12.12
min) are structural isomers, both having molecular masses of 206. Chromatographic separation
was not achieved for the next pair of structural isomers, naphthalene-1,6-dimethyl-4-(1101

methylethyl) and 1,4-dimethyl-7-isopropyl azulene (MW = 198), which coeluted at 12.83 min.
However, confirmation was obtained by visual comparison of EI fragmentation patterns. The
next compound eluted was 2,4-di (1-phenylethyl) phenol, which has a molecular mass of 302.
The last compound eluted was 1,2-dihydro-3,5-dimethylbenz[J]aceanthrylene (MW = 284) at
17.21 min. In addition to the PAH metabolites, several long-chain alkane hydrocarbons ranging
from C16 to C35 were also detected in Sample 1.
Only three compounds were detected in sample 2 within a 10.55 min elution window
(Table 6.2). The first compound eluted was 4-Tert-butyl-1,2-benzenedithiol (198 Da) at 12.84
min. The second compound eluted was 1-Phenanthrene carboxylic acid at 16.72 min followed
by benz[a]anthracenone at 16.80. 1-phenanthrene carboxylic acid and benz [a] anthracenone are
singularly substations, making their structures very close to parent PAH compounds. Various
long-chain alkanes were also detected in sample 2.
6.4 Conclusions
Studies were conducted with atherosclerotic tissue specimens from two elderly subjects
to evaluate the feasibility of the proposed hybrid OLS-IAE method for the analysis of PAHs in
atherosclerotic plaque and tissue samples. GC-MS analyses of OLS-IAE extracts indicate that
PAH metabolites were present in both atherosclerotic plaque samples. A total of eight different
compounds were identified. As expected, the reversed phase elution orders for the compounds in
both samples were inversely proportional to the number of benzene rings contained in the
compounds. However, sample 1 contained the structural isomers naphthalene-1,6-dimethyl-4-(1methylethyl) and 1,4-dimethyl-7-isopropylazulene, which were

not chromatographically

resolved. The presence of the phonol derivative 2,4-di-tert-butylphenol may be indicative of in
vivo cytochrome P-450 enzymatic metabolism. Likewise, sample 2 contained two singularly
substituted metabolites, 1-phenanthrene carboxylic acid and benz[a]anthracenone, which may
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also be an indication of early stage cytochrome P-450 metabolism. Interestingly, sample 2 also
contained 4-tert-butyl-1,2-benzenedithiol, a non-PAH compound. The presence of the longchain hydrocarbons in both samples may be the result of thermal degradation of the reversed
phase GC column. Alternatively, this signal could also be due to degradation of fatty acids and
cholesterol esters in the atherosclerotic plaque.
Table 6.2 Structures of PAH metabolites detected in sample 1 (69 year old African American
male), molecular masses (MW) and retention times.
Compound Detected
(molecular mass)

Structure

Retention Time
(min)
OH

2,4-di-tert-butylphenol
(206)

11.38

[1-S-(1a,3ab,4a,8ab)]decahydro-4,8,8′trimethyl-9-methylene1,4-methanoazulene
(206)

12.12

naphthalene, 1,6dimethyl-4-(1methylethyl)
(198)

12.83

1,4-dimethyl-7isopropylazulene
(198)

12.83

1,2-dihydro-3,5dimethylbenz[J]
aceanthrylene
(284)

17.21
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Table 6.3 Structures of PAH metabolites detected in sample 2 (70 year old Caucasian male),
molecular masses (MW) and retention times.
Compound Detected
(molecular mass)

Structure

Retention Time
(min)

HS

4-tert-butyl-1,2benzenedithiol
(198)

1-phenanthrene
carboxylic acid
(222)

12.84

HS

HO

16.72
O

benz[a]anthracenone
(302)

16.80
O

These preliminary results suggest that proposed OLS-IAE method is viable. Future
studies may address the inclusion of suitable internal standards for validation studies. The use of
tandem MS (MS-MS) could further improve the method by allowing for greater certainty in PAH
compound identification. The resultant method could be useful for studying the relationship
between PAH bioaccumulation and CVD, which could shed light on the relationship between
tobacco smoking and atherosclerosis.
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CHAPTER 7
SUMMARY OF RESEARCH AND FUTURE STUDIES
This dissertation is a chronicle of recent work in our laboratory to develop novel
bioanalytical methods for the analysis of Hcy and related CVD indicators. Throughout this
work, emphasis was placed on gaining a better understanding of the physiochemical mechanisms
critical to bioanalytical method development.

In addition, updated nanotechnology-based

research initiatives were implemented to address the lack of effective analytical methods for NHcy-protein. This chapter provides a summary of research and recommendations for future
research.
The first chapter of this dissertation contains a review of the relevant literature and an
introduction of the objectives and scope of research. Chapter 2 is a report of fundamental
spectrochemical studies pertaining to in vitro PT formation.

Pyridoxal-5-phosphate was

exhibited chemical reactivity toward Hcy under physiological pH conditions. Benesi-Hildebrand
analysis of the fluorescence data suggested 1:2 [pyridoxal:Hcy] binding stoichometry. One Hcy
molecule is covalently bound to the aldehyde group of pyridoxal. The other Hcy molecule is
weakly associated with the pyridoxal phosphate group via ionic interactions. The preliminary
findings support the feasibility of the PT-Hcy sequestration-clearance hypothesis. In Chapter 3,
we discuss using electrophoretic separation as a means of examining the effect of pyridoxal on in
vitro protein N-homocysteinylation. CE separations were performed with cationic polymercoated capillaries, which allowed highly efficient separations without significant non-specific
protein binding. The short-end injection format was utilized to obtain more rapid separations
and shorter analysis times, usually less than 2 min. The optimized method was subsequently
used to further investigate the validity of PT-Hcy sequestration-clearance hypothesis. It was
shown that PT formation competes with the N-homocysteinylation protein reaction, thereby
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inhibiting in vitro post-translational modification. This finding provides additional empirical
support for pyridoxal-mediated Hcy clearance.
Plasmon resonant GNP sensing of N-Hcy-protein was introduced in Chapter 4. GNPs
were proven to be a viable alternative to conventional bioanalytical methods such as HPLC and
ELISA for selective detection. Direct colorimetric sensing of in vitro-synthesized N-Hcy-serum
protein was accomplished via modification-directed nanoparticle assembly, which caused a shift
in GNP plasmon resonance. The resultant GNP assemblies appeared to exhibit irreversible
association characteristics even at elevated temperatures. In fact, the colorimetric response was
enhanced by heating the sensor-protein solutions at 80 ºC.

Further investigations of the

physiochemical mechanisms involved in GNP sensing of N-Hcy-protein were discussed in
Chapter 5. GNP-protein bioconjugates prepared from albumin, cyt c, and serum, respectively,
were subjected to in vitro N-homocysteinylation and monitored with various spectroscopic
methods in order to assess nanoparticle assembly size and modification-induced protein
conformational changes. Nanobioconjugate self-assembly was found to be dependent on protein
susceptibility toward N-homocysteinylation.

Consequently, cyt c nanobioconjugates yielded

the highest degree of self-assembly and the largest shift in plasmon resonance. CD experiments
revealed that modification-induced changes in protein conformation were most detectable after
heating at 80 ºC, thereby indicating the possibility of protein denaturation.

Assembled

nanobioconjugates were also subjected to SDS-PAGE separation under reducing conditions in
order to probe the mechanism of association.
association

is

the

result

of

disulfide

Gel separations indicated that interparticle
cross-linking

among

N-homocysteinylated

nanobioconjugates.
In Chapter 6, the poor of quality of GC-MS analysis of PAHs in atherosclerotic plaques
was addressed. The proposed solution was a hybrid organic solvent-immunoaffinity technique
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that provided selective PAH extraction. First, liquid-solid extraction was performed on the
plaque samples. Aqueous solvent exchange was subsequently performed on the organic extract
to give a phosphate buffered sample. The resultant solution was further extracted with an IAE
column. Unlike normal organic extraction, the hybrid method allowed for detection of several
PAH metabolites in two different atherosclerotic plaque samples. These preliminary results
demonstrated the potential utility of the hybrid extraction method for GC-MS plaque
characterizations.
Perhaps the most promising aspect of this dissertation is the demonstrated use of plasmon
resonant GNP sensors for detection of N-Hcy-protein screening. The ultimate goal of this
project is to development a reliable clinical screening method. Realization of this goal will likely
involve three phases; 1) further optimization of the current method, 2) incorporation of an
immunoaffinity component, and 3) clinical evaluations. Efforts to optimize the current sensing
method are ongoing. Experimental parameters such as and GNP size, protein concentration, and
buffering conditions have been identified for further study.

The next logical step is to

immobilize an immunoaffinity ligand to the GNPs in order to attain enhanced selectivity. Both
antibodies and aptamers should be considered. Antibodies for N-Hcy-protein are not
commercially available; however, it may be possible to obtain them from other researchers or
custom antibody producers. Alternatively, aptamers could be employed as the immunoaffinity
component. Aptamers are oligonucleotide sequences that can be engineered with specificity to
N-Hcy-protein. Departmental resources and expertise are currently available to assist in the
development of aptamers. An effort should also be made to demonstrate the use of the sensor in
a 96-well format, which would dramatically increase sample throughput.

GNP plasmon

resonance absorption and fluorescent labeled immunoaffinity ligands are potential detection
options. Having already established a working relationship with the Pennington Biomedical
108

Research Center, the optimized high throughput immunoaffinity sensing scheme could be tested
and validated with a large number of clinical serum samples. The finalized method could help
establish the usefulness of N-Hcy-protein as a CVD biomarker.
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APPENDIX A: CHARACTERIZATIONS OF PROTEIN AND PYRIDOXAL
REACTIONS
Table of Content
Figure A.1: MALDI-TOF mass spectrum for the protein reaction mixture.
Figure A.2: Black and white photograph of SDS-PAGE separation of protein reaction
mixtures treated with pyridoxal-5-phosphate.
Figure A.3: UV-Vis Spectrophometric study of in situ pyridoxal tetrahydrothiazine
formation in protein reaction mixtures treated with pyridoxal-5-phosphate.

Figure A.1 MALDI-TOF mass spectrum for the protein reaction mixture (10 mg/mL bovine
cyt c + 2.5 mM homocysteine thiolactone) acquired after 24 hrs. The molecular ion (M+H)+
for monomeric bovine cyt c was detected at approximately 12.3 kDal, which is consistent
with the literature. The roman numerals indicate molecular ion species corresponding to
monomeric (I), dimeric (II), trimeric (III), tetrameric (IV), and pentameric (V) bovine cyt c.
The peak preceding the monomer molecular ion is due to the doubly protonated monomeric
species. The minor peaks preceding the aggregate molecular ion peaks are due to various
trace higher order aggregate species.
Mass spectrometry experiments were performed using a Bruker ProFLEX III™
matrix assisted laser desorption ionization time of flight- mass spectrometer (MALDI TOFMS) in linear mode with a sinapinic acid (SA) matrix. The matrix was prepared by
dissolving SA in a 2:3 acetonitrile/0.1% TFA mixture to obtain a 10 mg/mL SA solution.
Protein reaction mixture samples and SA were mixed to obtain a 1:1 protein/matrix solution.
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The resultant solution was deposited drop-wise onto a MALDI target and allowed to dry and
crystallize. Mass spectra were acquired using 100 shots with a 0 ns delay. Relevant
instrumental parameters: linear mode, 100 shots, 0 ns delay, and sinapinic acid matrix.

Figure A.2 Bovine cyt c and hcy thiolactone (10 mg/mL and 2.5 mM, respectively) were
reacted with pyridoxal-5-phosphate (PLP) for 24 h at room temperature. The resultant
samples were denatured by heating at 95°C for 5 min in the presence of SDS and separated
using SDS-PAGE on 4–20% gels at approximately pH 9. A representative gel is shown
above. Unmodified cyt c migrated as a single band (lane 1). Lanes 2-6 show 1:0, 1:0.25,
1:0.5, 1:0.75, and 1:1 hcy thiolactone:PLP, respectively. Cyt c monomers, dimers, and
trimers are denoted as I, II, and II, respectively as determined by comparison with protein
mass standards (lane 0). Note the decrease in aggregate band intensities as the concentration
of PLP increases, eventually resulting in the disappearance of the trimeric species as well as
an appreciable reduction in the dimeric species.
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a)

b)

Figure A.3 Spectrophotometric detection of in situ pyridoxal tetrahydrothiazine formation
after 12 h in a) control reaction mixtures containing 2.5 mM Hcy thiolactone and PLP in the
indicated concentrations (inset: pyridoxal tetrahydrothiazine production monitored at 330
nm), and b) protein reaction mixtures containing 10 mg/mL bovine cyt c, 2.5 mM Hcy
thiolactone, and PLP in the indicated concentrations after 12 h. All samples were diluted 10fold with pH 7.4, 100 mM sodium phosphate, 0.2 mM EDTA buffer prior to analysis. UVVis spectra acquired in triplicate at 25°C using a Shimadzu model UV-3101PC
spectrophotometer equipped with a 1 cm quartz cell.
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APPENDIX B: GOLD NANOSENSOR CHARACTERIZATIONS AND
CALIBRATION DATA
Contents
Figure B1: MS data for unmodified and HTL-modified albumin
Figure B2: Calibration curve for GNP sensor response
Figure B3: TEM images of regions within oligomeric protein network containing GNP
clusters
Figure B4: Dilution stability study for the GNP sensor
a)

b)
a)

c)

d)

Figure B1. Mass spectra for a) the monomeric, b) the dimeric mass regions, respectively, of
an unmodified HSA (control sample). Mass spectra for c) the monomeric and d) dimeric
mass regions, respectively, of an HTL-modified HSA sample illustrate the extent of
modification produced in the protein reaction mixture.
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y = (2.7 × 10-3) x + 1.0 × 10-1
r2 = 0.9849

Figure B2. GNP sensor response at 620 nm to HSA-homocystamide (2.8 – 28 mg/mL),
assuming complete modification. Each data point is the average of triplicate measurements.

Figure B3. Transmission electron micrograph (TEM) images of the GNP sensor in the presence of
HSA-homocystamide. The circled regions a) and b) highlight regions within the oligomeric protein
network containing 4-GNP clusters at 33,000 × magnification. The inset shows a) at 100,000 ×
magnification. Region c) contains a 2-GNP cluster ( 33,000 × magnification).
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y = (3.0 × 10-4) x + 5.1 × 10-4
r2 = 0.9899

Figure B4. The dilutional stability of the sensor-protein homocystamide complex was
evaluated by serial dilution of a sensor solution containing the GNP-protein complex (2.3
mg/mL sera homocystamide and 0.7 mM GNP). The concentration of the sensor complex in
reported in unit of µg/mL serum protein, assuming complete modification. Deviation from
linearity is indicative of a weakly bound complex; while linearity is indicative of a tightly
bound complex. The calibration sensitivity is 0.30 AU · (ng/mL)-1. This data suggest that the
colorimetric complex resulting from modification-induced nanoparticle assembly is
irreversible under the conditions used in this study.
Each data point is the average of 5
measurements.
Breif Discussion of MS data (Figure B.1)
ESI-MS was employed to verify HTPM and assess the extent of modification obtained
for the protein modification protocol used in study.

Fresh protein reaction mixtures were

prepared and diluted with water to obtain a 1 mg/mL solution. The resultant solution was further
diluted 2-fold with a 1:1 (acetonitrile:water) prior to injection onto an LC-MS column. The total
elapsed time from the initiation of the modification reaction to MS analysis was 6 hr. Note that
the predominant species in the control sample is monomeric HSA (66559 amu). A small signal
115

corresponding to naturally occurring dimeric HSA, ~25% relative intensity, was also detected in
the control sample. In contrast, the signal due to the unmodified HSA species (66558 amu) is
greatly diminished in the modified sample. The differences in amu between consecutive species
in the monomeric region of the mass spectra for the modified sample are ~117 amu, which is
consistent with the formation protein homocystamide formation via dipeptide bond formation,
which results in the loss of H2O (18 amu). Substantial signals from singularly and doubly
modified HSA species are detected at 66676 and 66791 amu, respectively. A smaller signal
corresponding to triply modified HSA is also observed. Additionally, there is a substantial
increase in the signals corresponding to dimeric HSA species in the protein reaction mixture due
to modification-induced oligomerization.
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APPENDIX C: NANOBIOCONJUGATE CHARACTERIZATIONS
Contents
Figure C1: TEM images of unmodified protein nanobioconjugates
Figure C2: UV-vis absorption study for N-homocysteinylation of CGNP nanobioconjugates
Figure C3: UV-vis absorption study for N-homocysteinylation of AGNP and SGNP
nanobioconjugates
a)

b)

c)

Figure C1. TEM images of unmodified nanobioconjugates. a) CGNPs, b) (AGNPs, and c)
SGNPs. Note that some of the GNPs are irregularly shaped due to the dried protein coating.
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Figure C2. UV-vis absorption spectra acquired at 620 nm (25 ºC) over a 28 minute time
period for N-homocysteinylation of a) CGNPs. Each data point represents the average of
triplicate measurements.
UV-vis spectroscopy used to monitor the effect of N-homocysteinylation on the
plasmon resonance behavior of the CGNP systems at 25 ºC. Self-assembly resulting from Nhomocysteinylation of CGNPs was monitored at at 620 nm for 28 min. Extended plasmon
resonance absorption intensity for modified CGNPs increased over a period of approximately
10 min, which indicates the formation of nanobioconjugate assemblies.
a)
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b)

Figure C3. UV-vis absorption data acquired at 620nm (60ºC) over a 28 minute time period
for N-homocysteinylation of a) AGNPs and b) HGNPs illustrate the growth of nanoparticle
assemblies. Each data point represents the average of triplicate measurements.
UV-vis spectroscopy was also employed to monitor the effect of Nhomocysteinylation on the plasmon resonance behaviors of AGNPs and SGNPs. Absorption
spectra were acquired at 620 nm over a period of 28 minutes at 60 ºC, highest temperature
attainable for the instrumentation. An initial decrease in absorbance at 620 nm was observed
upon N-homocysteinylation of AGNPs (Figure C3a). Subsequently, there was a steady
increase in absorption, which indicates the formation of nanobioconjugate assemblies. The
SGNP system behaved nearly identical to the AGNP system (Figure C3b). Collectively,
these data correspond to the DLS trends discussed in the text (Figure 5.2).
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